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Chapter I. Introduction 
 
 
 
 
 
As a crucial step in many bacterial infections, pathogens employ their adhesins 
that include lectins, to bind specific carbohydrates on the surface epithelium, mucous 
glycoproteins, and glycolipids of the host to get attached and start colonization (1,2).  In 
the ‘notorious’ respiratory infections in cystic fibrosis (CF) patients, Pseudomonas 
aeruginosa, the major bacterial pathogen, is considered to utilize two lectins, LecA and 
LecB (also known as PA-IL and PA-IIL), together with some other carbohydrate-binding 
structures (adhesins), to bind certain sugars on the CF airway surface (3-6).  For several 
reasons, the bacterial infection in CF lungs is extremely difficult, if not impossible, to be 
eliminated by any current antibiotics.  In the pursuit of new anti-bacterial therapeutics, 
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anti-adhesion therapy utilizing competitive carbohydrates to block the lectin-mediated 
bacterial binding offers a promising treatment for both CF and non-CF patients (7,8).  
Within the respiratory tract of CF patients, P. aeruginosa normally first appear as motile 
and non-mucoid, which is the typical morphology of environmental isolates.  Over time, 
as a result of the environmental stresses and the formation of biofilms (9,10), clinically 
isolated P. aeruginosa often presents a wide range of phenotypic diversities, including 
the appearance of different colony morphologies, numerous physiological 
heterogeneities, and varied expression levels of virulence factors, to name a few (11,12).  
Lectins and other sugar-binding proteins are considered to be important virulence factors 
of P. aeruginosa, and their individual binding specificities have been extensively studied 
in the last several decades.  However, the monosaccharide-binding profiles of different 
morphotypes haven’t been thoroughly investigated on the cellular level.  Due to the small 
sizes of the bacteria and low binding affinities of many lectins with monomeric 
carbohydrate ligands, studying bacterial carbohydrate-binding has always been 
challenging. 
Therefore, the two major aims of this doctoral research project are:  
1). Establish improved methodologies to investigate the lectin-mediated bacterial 
binding with carbohydrates.  
2). Determine the monosaccharide-binding profiles of clinical CF P. aeruginosa 
isolates with different colony morphologies. 
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1. Cystic fibrosis  
CF is one of the most common genetic disorders in Caucasians (~1 in 3000 
births).  As an autosomal recessive disease, CF is caused by mutations in the gene 
encoding the CF transmembrane conductance regulator (CFTR).  Expressed in exocrine 
tissues, CFTR functions primarily as a chloride channel secreting Cl– to the airway 
surface, and the inhibitor of an epithelial Na+ channel preventing sodium reabsorption 
back into cells (13,14).  Out of  more than 1,800 known CFTR mutations (15), the most 
common one is an in-frame three-base deletion that leads to the loss of the amino acid 
phenylalanine (F) at position 508 (ΔF508) (16).  This causes a folding defect of the 
protein, which is recognized by the quality control mechanisms in the endoplasmic 
reticulum, where the misfolded protein is ubiquinated and marked for degradation (17).  
About 87% of the CF patients in the U.S. have at least one copy of the ΔF508 mutation, 
and ~47% have two copies (15).    
The symptoms of CF, resulted from functional disorder of exocrine tissues, 
include progressive infection and inflammation in airways, faulty digestion due to 
pancreatic insufficiency, diabetes caused by destruction of the pancreas, male infertility 
because of the congenital bilateral absence of the vas deferens, excessive loss of salt in 
sweat, etc (18).  In the airway, the malfunction of CFTR causes reduced secretion of 
chloride into the lumen and decreased inhibition of Na+ reabsorption.  While elevated 
amount of salt is retained in the epithelial cells, water follows from the lumen into the 
cells, leaving highly dehydrated and tenacious mucus on the respiratory tract surface.  
Therefore, the protection offered by the mucociliary movement in normal individuals are 
now highly compromised, and the mucous layer, in turn, becomes a habitat for bacteria 
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(18,19).  Albeit many other organs are affected by this genetic disorder as well, the 
patients’ survival is primarily decided by the progression of their lung diseases (85% of 
the mortality), characterized by chronic inflammation and infection with a number of 
bacterial pathogens, including P. aeruginosa, Staphylococcus aureus, Haemophilus 
influenzae, Burkholderia cepacia (a complex of at least nine species), etc (15,20).  In 
general, CF infants are rapidly colonized by S. aureus and, progressively, P. aeruginosa 
becomes predominant in the airway (21).  According to the annual report by the US CF 
Foundation, S. aureus can be found in the lungs of ~70% of the CF patients under the age 
of 10, and only ~25% of the patients at this stage show P. aeruginosa infection, whereas 
more than 70% of the CF patients older than 25 are infected by  
P. aeruginosa, and the number for S. aureus infection drops to ~55%.  The CF airway 
becomes a P. aeruginosa habitat for several possible reasons: permissive 
microenvironments within the mucous plaques anaerobic niches, increased bacterial 
binding to the airway surface, and compromised bacterial clearance via innate immune 
mechanisms (18,22). 
For chronic pulmonary disease treatment, the 2013 CF Foundation guideline 
recommends inhaled tobramycin (an aminoglycoside antibiotic), aztreonam (a β-lactam 
antibiotic) and dornase alfa (recombinant human DNase) for patients with moderate to 
severe P. aeruginosa infections; the use of inhaled bronchodilator, hypertonic saline, and 
airway clearance techniques were also supported (23).  By virtue of earlier diagnosis 
through newborn screening, advanced treatment and better access to health care, the 
prognosis for CF patients has dramatically improved over the past decades.  The median 
predicted survival age in the U.S. has increased by almost 10 years in the last 
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decade―from age 31.3 in 2002 to age 41.1 in 2012 (15).  However, for CF patients with 
end-stage respiratory inflammation and infection, lung transplantation is often required.  
Therefore, new CF therapies are still actively sought (24,25).  
 
2. P. aeruginosa and biofilm 
Not only is P. aeruginosa a major pathogen in CF lung infections, but also a 
significant cause in many other human opportunistic infections, including burn victims, 
urinary-tract infections in catheterized patients, hospital-acquired pneumonia in patients 
on respirators, etc. (26).  As a ubiquitous Gram-negative rod, P. aeruginosa can be found 
in soil, water, animals and almost all man-made environments.  Transmitted via 
environmental reservoirs and by direct contact between carriers,  P. aeruginosa in CF 
lungs normally first appear as motile and non-mucoid, and can be cleared by the host, or 
eradicated with intensive antibiotic treatments (27).  Over time, in part due to the 
formation of biofilms, the bacteria start to demonstrate phenotypic diversities, and it 
becomes extremely difficult to eliminate the infection by any antibiotics (28).   
By definition, biofilm is a community formed by microorganisms that are 
attached to a surface and aggregate in a hydrated polymeric matrix.  The matrix is 
composed of exopolysaccharides (EPS), lipids, extracellular nucleic acids, and proteins 
(28,29), components that play distinct but all essential roles in the biofilm formation 
(29,30).  In the P. aeruginosa biofilm, three types of polysaccharides can be found: 
alginate, Psl and Pel, each of which offers different physiological properties to the 
biofilm matrix (31).  Alginate is dominant in mucoid bacteria (32), and Pel/Psl in non-
mucoid (33).  The exceptional high antibiotic resistance of P. aeruginosa within a biofilm 
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is partly caused by the slow drug penetration, oxygen limitation, and  low metabolic 
activity of the bacteria in the EPS matrix (34).  Within biofilms, P. aeruginosa vary their 
phenotypes to adapt to local microenvironments.  Frequent alterations include changes in 
surface antigens, overproduction of EPS, modulation of microaerobic metabolic 
pathways, etc. (35).  Consequently, P. aeruginosa isolated from CF patients often show a 
remarkably diverse colony morphologies: they can be mucoid or nonmucoid, motile or 
nonmotile, smooth or rough,  pigment-secreting or colorless, or in the form of small 
colony variants (36,37).  Many of these characteristics are directly related to bacterial 
virulence and increased antibiotic resistance (38).  Moreover, it has been demonstrated 
that phenotypic diversities of this Gram-negative bacteria can be observed after being 
cultured in a biofilm for 24 h (10), or contact with muco-purulent respiratory liquid from 
CF patients for only several hours (39).  These observations offer intriguing insights into 
the understanding of the diverse phenotypes of P. aeruginosa within CF lungs and the 
bacteria’s interactions with the hosts. 
In P. aeruginosa, part of the biofilm formation process, along with a considerable 
amount of different functions, are controlled by its two intertwined quorum sensing (QS) 
systems–Las and Rhl (40).  Employed to collectively control group behaviors, QS is a 
bacterial communication system that functions by producing and detecting signal 
molecules, namely autoinducers.  P. aeruginosa’s QS systems are composed of 
transcriptional regulatory proteins–LasR, RhlR and associated autoinducer: N-(3-
oxododecanoyl) homoserine lactone (in Las system) and N-butyryl homoserine lactone 
(in Rhl system) (41-43).  The complexes formed by LasR or RhlR with their 
corresponding autoinducers modulate the expression of target genes (44), among which 
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are those controlling the development of biofilm, expression of virulence factors, and 
sensibility to antibiotics (45).  Therefore, quorum sensing inhibitors that can potentially 
block biofilm formation and bacterial virulence offer latent novel antibiotics (46,47).  
 
3. Mucus and Mucins  
In addition to the formation of P. aeruginosa biofilm, another important reason 
for their persistence in CF lungs is the compromised mucociliary movement and cough 
clearance attributable to the dehydrated and viscous mucus in CF lungs (19,48).  Mucus 
is a frequently-used word that has an ambiguous definition.  It’s generally considered as 
the adhesive, viscoelastic, heterogeneous gel produced by goblet cells and submucosal 
glands that covers and protects apical surfaces of the respiratory, gastrointestinal, and 
reproductive epithelial tracts (49).  The presence of mucus, in cooperation with the ciliary 
movement, helps the clearance of invaders from our lungs.  However this protection 
mechanism is heavily damaged in CF patients (19,48).   
The two main causes for the compromised mucociliary clearance in CF are the 
dehydrated mucus due to the deficient ion channel CFTR and the overproduction of 
mucins―a major component of mucus (50).  Mucins are large glycosylated proteins (up 
to ~107 Da) produced by epithelial tissues with a signature feature of tandem repeat 
amino acids that are rich in serine and threonine (sites for O-linked glycosylation) (51).  
The schematic structure of mucin resembles a dumbbell, composed of two hydrophobic 
globules at the ends and a heavily O-glycosylated region in the middle (52), with glycans 
counting for >70% of the total weight of the molecules.  The three major respiratory 
mucins MUC2, MUC5AC and MUC5B (53) are all subject to regulation by CF 
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inflammatory stimuli.  MUC5AC and MUC5B can be overproduced in CF lung secretion 
(54,55), especially following exacerbations (50,56).  MUC2 gene expression can also be 
transcriptionally up-regulated by P. aeruginosa’s components (57,58).  The 
overexpression of mucins, in turn, contributes to the airway obstruction and impairment 
of mucociliary clearance of the bacteria (59).   
The non-reducing ends of respiratory mucin glycans are mostly composed of four 
types of monosaccharides: L-fucose, D-galactose, D-N-acetylgalactosamine, and D-N-
acetylneuraminic acid, some of which are occasionally sulfated (60,61).  Compared with 
healthy individuals, chronic inflammation patients often show altered levels of sulfated 
and sialylated carbohydrates on mucin glycans (62).  Sugars at the non-reducing ends of 
mucin glycans are the major players involved in the lectin-mediated bacterial binding 
with mucins.  
 
4. Lectins, P. aeruginosa binding to airway surface and anti-adhesion therapy 
Respiratory mucus in CF lungs becoming a habitat of P. aeruginosa is partially 
due to the bacteria’s propensities to bind mucin glycans through their lectins.  Lectins are 
proteins that bind specifically to certain saccharides, but do not originate from immune 
systems or have any known enzymatic activities.  The basic role of these ubiquitous 
proteins is to recognize carbohydrate residues on cells, glycoproteins, or glycolipids, 
leading to a variety of biological functions in animal, plants and microbes (63).  The 
minimum unit of sugars that can be specifically recognized by a lectin is defined as the 
primary saccharide, which is normally at the non-reducing end of a glycan.  And the 
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secondary saccharide refers to a neighboring part to the primary that can affect the lectin 
binding affinities.   
First discovered in 1888 by Stillmark in castor bean seeds, lectins are now known 
to be present throughout life forms in nature.  Based on the current statistics from the 3D 
Lectin Database, about 18% of the lectins discovered so far are from bacteria (221 out of 
1241).  In the microbial world, lectins tend to be called by other names, such as 
haemagglutinin or adhesins.  Bacterial lectins mainly function as either toxins or 
adhesins, interacting with their host cells and tissues.  A wide range of bacteria of their 
lectins and cognate receptors have been studied.  In the book entitled “Bacterial Adhesion 
to Animal Cells and Tissues”, edited by Itzhak Ofek et al in 2003, more than 4,000 
references covering ~290 bacteria species were included (64), many of which referred to 
bacterial lectins.  The carbohydrate-binding specificities of particular bacterial lectins are 
also being elucidated (65,66).  The best characterized are shiga toxin produced by 
Shigella dysenteria and three pili adhesins of Escherichia coli (65).   
P. aeruginosa produces two soluble lectins―LecA and LecB (3), which 
recognize α-D-galactose- and α-L-fucose-containing glycosides, respectively.  They were 
initially considered to be located in cell plasma (67), but LecB was then proposed to be 
located on the outer membrane of P. aeruginosa (68,69).  Although both lectins adopt a 
small jelly-roll β-sandwich fold and use Ca2+ in carbohydrate-binding, they don’t seem to 
be evolutionarily related (70).  Their exact functions are not very clear, but there have 
been many indications of their association with bacterial virulence (3,68).  Besides the 
two lectins, P. aeruginosa’s type- IV pili are also considered to be an adhesin, which can 
specifically bind the carbohydrate sequence β-GalNAc(1–4)-β-Gal (71).  Type-IV pili are 
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noncovalently-associated polymers of pilin monomers, and only the pilin at the tip seems 
to be able to bind saccharides (5).  Furthermore, two components of the 
flagellum―flagellar cap protein and flagellin, are also adhesins involved in the binding 
with respiratory mucins (72,73).  On a cellular level, numerous laboratory strains and 
clinical isolates of P. aeruginosa have been demonstrated to bind certain mucin glycans 
in vitro (74,75).  Besides mucins, respiratory epithelial cells can be bound by the bacteria 
as well, especially recent daughter cells and those with CFTR mutations (76,77).   
A variety of assays have been developed to explore the lectin-mediated bacterial 
binding with carbohydrates, including solid-phase binding assay, glycoconjugates 
binding tests, carbohydrate microarrays, binding inhibition tests, etc (78-80).  In these 
methods, fluorophore- or radio-labeled materials were often used to test the binding of 
bacteria or purified bacterial proteins to carbohydrates, mucins or respiratory epithelial 
cells.  In spite of the lack of consensus about the specific functions of each lectin during 
the binding process, a reservoir of carbohydrates that might be involved in the bacterial 
binding has been created (74), which can be used as a resource for our research. 
With this bacterial carbohydrate-binding information on hand, researchers have 
been trying to use competitive carbohydrates or carbohydrate analogs to inhibit the lectin-
mediated bacterial binding, and further eradicate infections.  Administrations of simple 
sugars or glycosides as anti-P. aeruginosa agents have shown encouraging results in vitro 
(81), in ex vivo (82), and in animal models (83).  Two clinical reports using this strategy 
have also been published.  In a case reported in Germany, an infant with serious P. 
aeruginosa respiratory infection after chemotherapy for neuroblastoma, which could not 
be treated with antibiotics effectively, was subjected to additional D-galactose and L-
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fucose inhalation (~3.6 mg of each, twice daily) and cured (8).  In a clinical trial with 
adult CF patients, also using D-galactose and L-fucose inhalation (180 mg of each, twice 
daily) as additional treatment for P. aeruginosa infection, encouraging results were 
reported (7).  In addition to these specific anti-adhesion targeting sugars, mannitol, xylitol 
(both sugar alcohols) and some polysaccharides (dextran, dextran sulphate, heparan, etc.), 
have been tested in animal models and in CF patients as well, showing discrepant 
findings (84-86).  The exact functions of these carbohydrates remain unclear, but their 
potential anti-adhesion effects should not be excluded.  
Another anti-adhesion therapy target attracting much attention is FimH―the 
adhesin subunit at the tip of type I pili in E. coli.  As a key virulence factor in the urinary 
tract E. coli infection, this mannose-binding adhesin is critical in several infection stages 
(87).  Since the first attempt to use methyl α-D-mannopyranoside as an anti-adhesion 
therapeutic (88), great effort has been devoted to designing α-mannose analogs with high 
competitive binding efficacies.  Two major strategies have been adopted to increase 
affinities towards lectins: monovalent inhibitors with novel aglycone moieties, and 
glycoconjugates with multivalent carbohydrate epitopes.  Both strategies have 
demonstrated promising results in cell/tissue cultures and animal models (6,89-93), and 
yet no clinical trials have been reported so far.  Using multivalent glycopolymers in anti-
adhesion tests may cause unfavorable cross-linking of bacteria (94).  But, in the 
investigation of bacterial carbohydrate-binding, these polymers have been instrumental. 
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5. Glycopolymers: application and preparation 
By definition, glycopolymers are synthetic polymers with pendant sugar residues 
(95).  Due to the low binding affinities of some lectins to target carbohydrates (Kd in the 
mM range), glycopolymers that are 102–104 more potent than monomeric sugars are of 
great interest in studying lectins (96,97).  These polymers are also being employed in 
several other fields, like targeted drug and gene deliveries (98-100), bio-compatible 
materials (101,102), and even disease treatments (103-105).  Several informative reviews 
have been published on this subject matter (106-108).   
Besides glycopolymers, a variety of glycoconjugates that afford multivalent 
carbohydrates have been developed, including saccharide-coated gold nanoparticles, 
quantum dots or nanotubes  (109-111); carbohydrates-conjugated peptides and proteins 
(112); dendritic glycoconjugates (113), etc.  Compared with other glycoconjugates, linear 
glycopolymers hold several advantages owing to their inherent flexibility, high efficacy, 
versatility in applications, and the structural comparability with mucins, making them 
ideal for lectin-mediated bacterial binding studies (114).   
The first linear glycopolymer was synthesized in 1978 using free radical 
polymerizations (115).  Since then, a number of polymerization techniques offering better 
control of the reactions have been applied in glycopolymer syntheses.  One of these 
methods is the reversible addition–fragmentation chain-transfer (RAFT) polymerization.  
As a type of living polymerization, RAFT reactions employ a chain transfer agent 
containing a thiocarbonylthio group to control the degree of polymerization and 
dispersity of the products (116).  First reported by Thang et al. in 1998 (117), RAFT 
polymerization was introduced in the glycopolymer preparation in 2003 (118), and 
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gained great attention.  Glycopolymers with different structures have been synthesized 
with RAFT agents, like star-shaped dendrimers, block copolymers, statistical random 
copolymers, etc. (119-121).  RAFT agents are popular in glycopolymer preparations for 
several reasons: 1) they provide predictable molecular weights and low dispersities of the 
products; 2) they are compatible with a variety of solvents, including aqueous 
environments, which is vital for synthesizing polymers with high contents of 
carbohydrates; 3) they are tolerant with a wide range of monomer’s functionalities and 
reaction temperatures varying from 25–70°C. 
 Other than the copolymerization strategy employed in synthesizing 
glycopolymers, another method using preactivated polymers was also proposed by 
Whitesides’ and Bovin’s groups separately in the 1990s (122,123).  Polymers 
preactivated by possessing active esters, like N-(acryloyloxy) succinimide and p-
nitrophenol acrylate, are then conjugated with glycoside and fluorophore side chains that 
contain primary amine functional groups through the formation of amide bonds.  
Compared with the copolymerization strategy to prepare glycopolymers, this 
preactivated-polymer method has its own advantages.  First, the length and dispersity of 
the polymer backbone are kept constant, if the same batch of preactivated polymer is 
used for all syntheses.  Second, the distribution of pendant sugars along the backbone is 
theoretically more uniform than that of copolymerization (122,124).  
In our preliminary carbohydrate-binding tests with P. aeruginosa, very 
encouraging results were obtained using commercial glycopolymers from Lectinity 
Holding (Moscow, Russia), which were prepared with the preactivated polymer method.  
However, the limited supply source and our intention to study the effects of polymer-
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structural variance on the bacterial binding tests prompted us to synthesize some of the 
glycopolymers on our own. 
In this dissertation, Chapter II describes our initial unproductive attempt to 
synthesize glycopolymers following the preactivated polymer method published by 
Bovin’s group (123).  Due to the absence of important reaction details in the literature, 
some syntheses procedures for the sugar side chains had to be developed based on other 
references.  Our efforts of using various reaction reagents and conditions to conjugate 
side chains onto the polymer backbone are included.  
Chapter III details the preparation of a panel of fluorescent glycopolymers using 
RAFT agents and the use of some of the polymers in lectin-binding tests.  In the 
preparation, (4-cyanopentanoic acid)-4-dithiobenzoate was used as the RAFT agent 
because of its compatibility with polar solvents and acrylamide/methacrylamide 
glycomonomers.  In the glycomonomers’ syntheses, a procedure proposed by Narain’s 
group to conjugate pendant sugar to acrylamide monomers was adopted with 
modifications (125).  The binding specificities and avidities of the synthesized 
glycopolymers were first confirmed with corresponding plant-lectins coated on agarose 
beads, and then utilized in bacterial binding tests. 
Chapter IV depicts our investigation of the carbohydrate-binding behaviors of a 
group of P. aeruginosa laboratory strains and clinical isolates from CF patients.  Using a 
panel of commercial fluorescent glycopolymers containing different glycosides, together 
with a number of analytical techniques, the monosaccharide-binding of this Gram-
negative bacterium was profiled. 
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Chapter V contains the discussion of the dissertation and possible future research 
directions of this work.   
The two major aims of this work listed at the beginning of this chapter were 
fulfilled.  Our efforts to establish an improved methodology to study bacterial 
carbohydrate-binding include the syntheses of the fluorescent glycopolymers and the 
development of methods of using these polymers with the aid of different analytical 
instruments.  The monosaccharide-binding profiles of P. aeruginosa are characterized in 
Chapter IV.  Employing the fluorescent glycopolymers and the procedures developed 
herein will help elucidate the carbohydrate-binding patterns of different bacterial 
pathogens that are of clinical significance, which is instrumental to improve our 
understanding of the pathogenesis of bacterial infections and provide new perspectives 
for the anti-adhesion therapies. 
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Chapter II. Preparation of Fluorescent Glycopolymers with 
Preactivated Polymer Poly(p-nitrophenyl acrylate) 
 
 
 
 
 
Introduction 
Polyacrylamide (PAA)-based fluorescent glycopolymers (structure shown in 
Figure II-1), have been used in a variety of lectin-mediated carbohydrate-binding studies 
(1-4).  Our initial tests employing PAA glycopolymers demonstrated that they could be 
very instrumental in P. aeruginosa carbohydrate-binding experiments.  Though these 
glycopolymers were commercially available, some of the products were not attainable in 
the amount required for our binding studies, and the delivery of the merchandise took an 
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unreasonably long time.  Because synthesizing some of these glycopolymers will provide 
us with better control over the structural variants of the glycopolymers, we decided to 
prepare some of the polymers. 
Two decades ago, Nicolai Bovin’s group in Moscow published a synthesis 
method for fluorescent glycopolymers (5).  In the protocol, which was claimed to be 
“very simple to carry out” (2), the authors prepared the p-nitrophenyl acrylate polymer 
backbone first, and then attached side chains containing primary amine functional groups 
onto the polymers through the formation of amide bonds.  Different side chains include 
glycosides, fluorescent tags, and ethanolamine (spacer on the polymer).  But due to the 
inadequate description of glycosides side chains preparations and the selection of 
fluorescent tags in the Bovin’s paper, the glycoside side chains syntheses were adopted 
from other literature sources and a series of fluorophores were tested in the reactions.  
The resultant glycopolymers were analyzed by gel permeation chromatography 
(GPC) for their molecular weights and dispersities, the sugar contents of the polymers 
were determined, and their lectin-mediated bacterial binding efficacies were tested with 
P. aeruginosa, using corresponding commercial glycopolymers as a positive control.  
 
Materials and Methods 
Materials 
Fluorophores were purchased from Life Technologies (Carlsbad, California).  The 
remaining chemicals were purchased from Sigma-Aldrich Chemicals (St Louis, MO).  
Unless mentioned otherwise, all chemicals were used as received.  Bacteria strains were 
obtained from ATCC (Manassas, VA).   
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Synthesis of 2-aminoethyl 2-acetamido-2-deoxy-β-D-galactopyranoside (see Schemes 
II-1) 
2-(Benzyloxycarbonyl)aminoethyl-2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-
galacto-pyranoside was prepared according to published methods with some 
modifications (6,7).  In brief, 1.0 g of β-D-galactosamine pentaacetate and 1.25 g of N-
Cbz-ethanolamine were dissolved in 10 mL of dry acetonitrile under Ar atmosphere.  The 
mixture was cooled to 0°C and 360 μL of SnCl4 was added dropwise.  The reaction was 
allowed to warm to room temperature and stirred at 75°C for 16 h.  The mixture was then 
allowed to cool to room temperature, quenched with 2 mL of triethylamine and 
concentrated under vacuum.  The residue was dissolved in 50 mL of CH2Cl2 and washed 
with water (3 x 30 mL), and the organic phase was dried over MgSO4 and evaporated.  
The products were separated by column chromatography (EtOAc/hexane 80:20 on silica), 
deacetylated with sodium methoxide, and hydrogenated with Pd/C to obtain 2-aminoethyl 
2-acetamido-2-deoxy-β-D-galactopyranoside (0.39 g, 58% yield, three steps). 
 
Synthesis of 1-amino-1-deoxy-melibiitol (see Schemes II-2) 
To 20 mL aqueous solution of 4.0 g of melibiose was added 7.5 mL of NH4OH 
and 6.65 mL of glacial acetic acid.  The mixture was stirred at 65°C for 1.5 h before 8.0 g 
of sodium cyanoborohydride were added.  The reaction was stirred at 650C for another 3 
h when TLC (1% acetic acid in MeOH) showed no free sugar left.  The volume of the 
reaction was then reduced under vacuum and a mixture of 100 mL of MeOH and 10 mL 
of isopropanol were added to precipitate the product, which was then washed twice with 
cold MeOH and dried under vacuum to yield the product as syrup (6.0 g).  The product 1-
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amino-1-deoxy-melibiitol was obtained by preparative TLC using n-butanol: acetic acid: 
water (2:1:1) as the solvent system (Rf=0.44, 1.58 g, 39% yield).  ESI-MS (in methanol: 
water 50:50): calculated m/z for C12H25O10N+Na
+, 366.13707; found m/z 366.13638. 
 
Synthesis of p-nitrophenyl acrylate and poly(p-nitrophenyl acrylate) (see Schemes 
II-3) 
p-Nitrophenyl acrylate was prepared according to a published method (8).  
Briefly, p-nitrophenol (21 g), 21 mL of triethylamine, and 150 mL of 2-butanone were 
mixed in a 1 L flask and 13 mL of acryloyl chloride was added dropwise to the mixture 
that was vigorously stirred in an ice bath.  The reaction was stirred for 1 h in the ice bath 
and another 16 h at room temperature.  The mixture was then evaporated and washed 
sequentially with water, 1% NaOH, very dilute acetic acid and once again water.  p-
Nitrophenyl acrylate was obtained from recrystallization from hexane (24 g, 83% yield). 
Poly(p-nitrophenyl acrylate) was synthesized based on a published method (5).  
To a 1 M solution of p-nitrophenyl acrylate in dry benzene were added 2,2′-azobis(2-
methylpropionitrile) (3% w/w to the monomer) under a stream of nitrogen and stirred at 
70°C for 50 h.  The benzene solution was then decanted and the brown residues were 
dissolved in dimethylformamide (DMF) to obtain a 1% solution.  The polymers were re-
precipitated with five volumes of methanol twice, and the clean white residue was 
washed again with methanol and dried to obtain the products (83% yield). 
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Synthesis of PAA-Glucamine-Fluor (see Schemes II-4) 
To a solution of 7.7 mg of poly (p-nitrophenyl acrylate) (40 µmol of phenol 
groups) in 2 mL of DMF, were added a solution of glucamine (1.45 mg) in 1.5 mL of 
DMF, fluorescence tags (molar ratio 1% to phenol groups, structures shown in Figure II-
2) in 0.5 mL of DMF, and 40 µL of triethylamine.  The mixture was stirred at room 
temperature for 16 h in the dark, and a 50-fold molar excess of ethanolamine (120 µL) 
was then added.  Following another 16 h of stirring at room temperature, the solution was 
dialyzed against distilled water (5 x 2 L) for 24 h (MWCO=7,500) and freeze-dried to 
obtain the products (6.5 mg), which were used without further purification.  
 
Synthesis of PAA-Sugar-Fluor (see Schemes II-5) 
DMF solutions (2 mL) containing various amount of 2-aminoethyl 2-acetamido-
2-deoxy-β-D-galactopyranoside or 1-amino-1-deoxy-melibiitol (molar ratio 20-50% to 
phenol groups) and different fluorescence tags (molar ratio 1-4% to phenol groups, 
structures shown in Figure II-2) were added to a solution of 7.7 mg of poly (p-nitrophenyl 
acrylate) (40 µmol phenol groups) in 2 mL of DMF, respectively.  Equivalent amount of 
triethylamine or diisopropylethylamine to the glycosides was then added.  The mixtures 
were stirred at room temperature or 60°C for 16–72 h in the dark, and 120 µL of 
ethanolamine was then added. Following another 16 h of stirring at room temperature, the 
solutions were then either dialyzed against distilled water 5 x 2 L for 24 h 
(MWCO=7,500) and freeze-dried, or precipitated in acetone and dried under vacuum.  
Polyacrylamide-based fluorescent glycopolymers possessing different ratios of pendant 
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α-D-galactoside (α-Gal) or β-D-N-acetylgalactosamine (β-GalNAc) and fluorophores 
were obtained and used without further purification. 
 
Analysis of glycopolymers 
Synthesized glycosides, dissolved in MeOH/water 50:50 (v/v) were subjected to 
direct electrospray mass spectrometry analyses, using a Thermo Scientific LTQ Orbitrap 
XL hybrid Fourier transform mass spectrometer.  Molecular weights and the dispersities 
of the glycopolymers were derived against a calibration curve from polyethylene glycol 
standards using a Waters Alliance HPLC system equipped with a refractive index 
detector (Waters e2695, 2414) and TOSOH TSK-GEL G4000 PWxl and a TSK-GEL 
G4000 SW GPC columns using 0.1M Tris/0.1M sodium chloride buffer (pH=7) as eluent 
at a flow rate of 0.6 mL/min.  Total carbohydrate content of the synthesized 
glycopolymers was analyzed according to a published protocol (9).   
 
Bacterial binding tests using synthesized fluorescent glycopolymers 
P. aeruginosa ATCC 39018 cultured on trypticase soy agar for 24 h were lifted 
and suspended in 20 mL of binding solution (155 mM NaCl, 1 mM CaCl2, and 1% 
bovine serum albumin) to attain a bacterial suspension with an optical density of 1.0 at 
600 nm.  For each binding experiment, 100 µg of the fluorescent glycopolymers 
dissolved in 100 µL sodium phosphate buffer (0.3 M, pH=7.4) were added to 1.0 mL of 
bacteria suspension, respectively.  Following 2 h of incubation at 35°C in the dark, the 
mixtures were centrifuged (8,000 x g, 10 min), and the pellets were washed three times 
with 1.2 mL of rinsing solution (155 mM NaCl, 1 mM CaCl2).  The final pellets were 
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then resuspended in 100 µL of PBS (pH=8.0), and aliquots were taken for analysis with 
fluorescence microscopy and fluorimetry.   
 
Results and discussion 
Based on the results from bacterial binding tests with commercial PAA-α-Gal-
Fluor and PAA-β-GalNAc-Fluor, P. aeruginosa can specifically bind these two sugars.  
However, the positive binding results could not be repeated with fluorescent 
glycopolymers synthesized in our laboratory.  
To investigate possible reasons of non-binding with bacteria, we tested various 
reaction conditions and reagents in the step of attaching the glycosides onto the polymer 
backbone that were reported by the Bovin’s group in different publications (5,10,11).  
These variants include different reaction times and temperatures, use of triethylamine or 
diisopropylethylamine, different stoichiometry of the reagents and purification methods.  
However, positive binding was still not observed.  Several reasons for the unsuccessful 
synthesis attempt can be speculated.  
First, the efficiency of attaching glycosides onto the polymer backbone might be 
lower than expected.  This speculation is supported by the fact that during the 
quantification of the total carbohydrate contents in the synthesized polymers, the actual 
molar ratios of the sugar side chains were always lower than the theoretical 
stoichiometric values.  For instance, only a molar ratio of ~7% of sugar side chains 
containing α-Gal was detected in the sugar profile test for the synthetic polymers from a 
reaction where a 20% molar ratio was used.  It should also be noted that due to the small 
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quantity of the available commercial PAA polymers, we were unable to confirm the 
content of sugar side chains to be 20% in their glycopolymers as claimed by the supplier.  
Second, the removal of the nitrophenol groups from the backbone might not be 
complete in the reactions, which could potentially interfere with the lectin-mediated 
bacterial binding with the glycopolymers.  During the characterization of the resultant 
glycopolymers, a new GPC column (TOSOH TSK-GEL G4000 PWxl) that was utilized 
to measure the molecular weights of the synthesized glycopolymer subsequently became 
dysfunctional, likely due to the minor presence of nitrophenol groups on the polymers or 
other reaction byproducts that could not be removed. 
Third, many details of the chemical syntheses, especially for the preparation of 
the glycoside side chains and the choice of fluorophores, were not included in any of the 
published manuscripts from Bovin’s group.  The difficulties of chemically analyzing the 
resultant glycopolymers and the absence of the required reaction details resulted in 
significant difficulties in the preparation of glycopolymers.  This unsuccessful 
preparation compelled us to adopt another synthesis strategy that is described in Chapter 
III.  
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Figure II-1. Schematic structure of PAA glycoconjugates. 
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Figure II-2. Fluorescent tags possessing primary amine functional groups used in 
this study. 
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Schemes II-1. Synthesis of 2-aminoethyl 2-acetamido-2-deoxy-β-D-
galactopyranoside. 
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Schemes II-2. Synthesis of 1-amino-1-deoxy-melibiitol. 
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Schemes II-3. Synthesis of p-nitrophenyl acrylate and poly(p-nitrophenyl acrylate). 
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Schemes II-4.  Synthesis of PAA-Glucamine-Fluor. 
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Schemes II-5. Synthesis of PAA-Sugar-Fluor. 
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Chapter III. RAFT-based Tri-component Fluorescent 
Glycopolymers: Synthesis, Characterization and Application 
in Lectin-mediated Bacterial Binding Study 
 
 
 
 
 
Abstract 
A group of fluorescent statistical glycopolymers, prepared via reversible addition- 
fragmentation chain-transfer (RAFT)-based polymerizations, were successfully employed 
in lectin-mediated bacterial binding studies.  The resultant glycopolymers contained three 
different monomers: N-(2-hydroxyethyl) acrylamide (HEAA), N-(2-aminoethyl) 
methacrylamide (AEMA), and N-(2-glyconamidoethyl)-methacrylamides possessing 
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different pendant sugars.  Low dispersities (≤1.32) and predictable degrees of 
polymerization were observed among the products.  After the polymerization, the 
glycopolymers were further modified by different succinimidyl ester fluorophores 
targeting the primary amine groups on AEMA.  With their binding specificities being 
confirmed by testing with lectin coated agarose beads, the glycopolymers were employed 
in bacterial binding studies, where polymers containing α-galactose or β-galactose as the 
pendant sugar were specifically bound by two clinically important pathogens 
Pseudomonas aeruginosa and Staphylococcus aureus, respectively.  This is the first 
report of using RAFT-based glycopolymers in bacterial binding studies, and the ready 
access to tri-component statistical glycopolymers also warrants further exploration of 
their utility in other glycobiological applications. 
 
Introduction 
In the past two decades, the use of synthetic glycopolymers in biochemical and 
biomedical research areas has acquired widespread attention.  Various types of 
glycoconjugates were applied in studies of lectin recognition processes (1-3), drug and 
gene delivery systems (2,4,5), disease treatments (6-9), to note a few.  Among different 
designs of glycoconjugate structures, linear glycopolymers with pendant carbohydrate 
moieties have certain advantages because of the inherent flexibility, efficacy, and their 
structural comparability with some natural glycoproteins, making them very suitable for 
cell-carbohydrates recognition studies (3).  In our clinical research, we are particularly 
interested in the lectin-carbohydrate interactions of key pathogenic bacteria with surface 
carbohydrates that are found on human tissue cell surfaces and extracellular matrices, a 
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process that is considered to be highly involved in the initial step of bacterial adhesion 
and the persistence of some infections (10,11).  Many important human respiratory 
pathogenic bacteria, like Pseudomonas aeruginosa, Staphylococcus aureus, Helicobacter 
pylori, Escherichia coli, etc., have been widely studied in their lectin binding behaviors 
(12).  Due to the naturally low binding affinities of many lectins to target carbohydrates, 
especially monosaccharides, multivalent glycoconjugates possessing higher lectin 
binding affinities are of great advantage in studying bacterial lectins (3).  Our initial 
success with the use of commercially available polyacrylamide-based glycoconjugates in 
the phenotypic expression of lectins of human respiratory pathogenic bacteria prompted 
us to develop a facile approach to well-defined polymers that would allow for varied 
pendant carbohydrates, along with different fluorescent labels. 
In this pursuit, we turned our attention to a type of living or controlled radical 
polymerization using reversible addition−fragmentation chain-transfer agents (RAFT) 
(13) that have been successfully applied in the synthesis of glycopolymers.  Specifically, 
the RAFT reactions demonstrate tolerance of a diversity of participating monomers and 
reaction conditions, as well as, the low dispersity of the products (14-16), all of which are 
desirable characteristics.  Several excellent reviews have been published on the utilization 
of RAFT in preparing glycopolymers (16-18).  Tri-component glycopolymers have also 
been synthesized through RAFT-based reactions, however, most of them either used 
stepped polymerizations to prepare tri-block copolymers (19-21) or did not possess 
anomeric pendant sugars appropriate for lectin-binding studies (22).  To the best of our 
knowledge, this is the first report of well-defined statistical tri-component glycopolymers 
prepared via one-step RAFT reactions, which possess varied pendant carbohydrates, the 
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versatility of post-modification with varied fluorescent labels, and demonstrated utility in 
targeted lectin-mediated bacterial binding. 
 
Materials and methods 
Materials   
Unless mentioned otherwise, all chemicals were used as received.  N-(2-
aminoethyl) methacrylamide hydrochloride was purchased from Polysciences 
(Warrington, PA).  Texas Red-X succinimidyl ester and 5-(and-6)-carboxyfluorescein 
succinimidyl ester were bought from Molecular Probes (Grand Island, NY).  Marasmius 
oreades agglutinin coated lectin beads were obtained from EY laboratories (San Mateo, 
CA), Galanthus nivalis lectin (GNL) and peanut agglutinin lectin beads from Vector 
Laboratories (Burlingame, CA).  Bacteria strains were from ATCC (Manassas, VA).  
TOSOH TSK-GEL G4000 PWxl (30 cm x 7.8 mm) and G4000 SW (30 cm x 7.5 mm) 
HPLC columns were from Fisher Scientific (Pittsburgh, PA).  Anion-exchange resin 
(Amberlite IRN-78 hydroxide-form, 80 mesh), cation-exchange resin (Dowex 50Wx8, 
200 mesh), hydroquinone monomethyl ether (MEHQ), Orange II sodium salt, N-(2-
hydroxyethyl) acrylamide (HEAA), and other chemicals, not noted above, were 
purchased from Sigma-Aldrich Chemicals (St. Louis, MO). The chemical structures of 
some of key reagents used in this study are shown in Figure III-1. 
 
Synthesis of disaccharides (see Scheme III-1) 
Disaccharides employed in this study, namely β-D-galactopyranosyl-(1→6)-D-
glucose (allolactose) and α-D-mannopyranosyl-(1→6)-D-glucose were prepared through a 
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modified Koenigs-Knorr reaction.  As an example, 1.0 g of 1,2,3,4-tetra-O-acetyl-β-D-
glucopyranose (23) (2.87 mmol) was dissolved in 10.0 mL dry CH3CN.  To the solution, 
1.2 g of 2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl bromide (2.92 mmol) and 0.8 g 
mercury (II) cyanide (3.12 mmol) were added.  The reaction was stirred for 16 h under an 
argon atmosphere at room temperature, at which time 2.0 mL of pyridine and acetic 
anhydride were added.  The stirring continued for 5 min at 60°C, at which time the 
volume of the reaction mixture was reduced in vacuo.  The syrupy residue was then 
redissolved in 200 mL of CH2Cl2, washed successively with water, saturated NaHCO3, 
and brine, then dried over MgSO4 and concentrated in vacuo.  The residue was purified 
by flash chromatography on a silica gel column (70-230 mesh, 60Å, 15mm x 50mm, 
ethyl acetate/hexane 1:1), yielding 1,2,3,4,2′,3′,4′,6′-octa-O-acetyl-β-allolactose (1.65 g, 
85% yield) as a colorless syrup.  
Under an atmosphere of dry nitrogen, per-O-acetyl-β-allolactose (1.0 g, 1.47 
mmol) was then dissolved in 150 mL dry MeOH, to which was added, with rapid stirring, 
1.5 mL of a sodium methoxide solution (25 wt. % in dry MeOH) over a 2 min period.  
The reaction was stirred for an additional 30 min at room temperature and stopped by the 
addition of cation-exchange resin (Dowex 50W×8, H+ form).  The resin was removed by 
filtration and the filtrate evaporated in vacuo to yield allolactose (0.49g, 97% yield).   
Synthesis of 6-O-α-D-mannopyranosyl-D-glucose, prepared in a similar manner, 
yielded 0.56g (80% yield) of the disaccharide. 
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Synthesis of disaccharide lactones (see Scheme III-2) 
Disaccharides melibiose, lactose, allolactose, and 6-O-α-D-mannopyranosyl-D-
glucose, employed in this study, were first oxidized to their corresponding lactones 
according to Moore, et al. (24).  As an example, 2.0 g of melibiose (5.84 mmol) were 
dissolved in 4.0 mL of water, diluted with 5.0 mL MeOH, and then added to 40 mL of 
MeOH containing 2.9 g of iodine at 40°C.  With stirring, 70 mL of 4% (w/v) KOH in 
MeOH was then added dropwise over a period of 30 min until the iodine color 
completely disappeared.  The mixture was then cooled on ice for 1 h.  The precipitate of 
potassium melibionate was then filtered, rinsed with cold MeOH, recrystallized from 100 
mL MeOH/water (9:1, v/v), then dried in vacuo.  The resulting melibionic acid salt was 
then dissolved in 10 mL water and converted into its free acid form by passing the 
solution through a strongly acidic cation-exchange column (Dowex 50W×8, H+ form) 
and then freeze-dried to yield approximately 2.0 g.  This was then dissolved in a minimal 
amount of MeOH (~3.0 mL) to which absolute EtOH was added until the solution turned 
just cloudy, at which time the solvents were evaporated in vacuo.  This was repeated 4 
times to yield melibiono-1,5-lactone (1.94 g, 98% yield).  Other disaccharides, oxidized 
in a similar manner, produced comparable yields (>95%). 
 
Synthesis of glycomonomers   
2-Gluconamidoethyl methacrylamide (GAEMA) and 2-lactobionamidoethyl 
methacrylamide (LAEMA) 
2-Gluconamidoethyl methacrylamide (GAEMA) was prepared according to a 
published protocol (19) and 2-lactobionamidoethyl methacrylamide (LAEMA) was 
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prepared with some modifications.  To the solution of 1.0 g of lactobiono-1,5-lactone 
(2.94 mmol) in 3.0 mL of MeOH, were added N-(2-aminoethyl) methacrylamide 
hydrochloride (AEMA· HCl, 0.58 g, 3.53 mmol) and 1.0 mg hydroquinone monomethyl 
ether (MEHQ, an inhibitor of self-polymerization) in 2.0 mL of MeOH and1.0 mL of 
triethylamine.  The mixture was stirred at room temperature for 48 h, at which time 20 
mL of water was added.  Then, MeOH and triethylamine were removed from the mixture 
in vacuo.  To remove any remaining lactobionate, the resulting aqueous solution was 
passed through an anion exchange column (Amberlite IRN-78, OH- form, 10 mm x 20 
mm) into a receiving beaker containing 1.0 mg of MEHQ.  Residual triethylamine was 
then removed from the eluate in vacuo.  Dowex 50W×8 (H+) was added portionwise to 
the solution, until no ninhydrin reactive material remained.  The mixture was then filtered 
and freeze-dried.  Removal of MEHQ from the freeze-dried product was accomplished 
by dissolving the material in a minimum amount of MeOH, which was then added to ice 
cold acetone to precipitate LAEMA.  Following filtration and drying, LAEMA (0.89 g, 
65% yield) was obtained as white powder. The purity and structure of the final product 
were confirmed by 1H NMR, 13C NMR and mass spectrometry (Figure III-2, 3). Anal. 
Calcd for C18H32N2O12+3/2H2O: C, 43.63; H, 7.12; N, 5.65. Found: C, 43.80; H, 7.00; N, 
5.40% 
 
2-Allolactobionamidoethyl methacrylamide (ALAEMA, see Scheme III-3) 
To the solution of 1.0 g of allolactobionolactone (2.94 mmol) in 3.0 mL of 
MeOH, were added N-(2-aminoethyl) methacrylamide hydrochloride (AEMA, 0.58 g, 
3.53 mmol) and hydroquinone monomethyl ether (MEHQ, 1.0 mg) in 2.0 mL of MeOH 
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and1.0 mL of triethylamine.  The mixture was stirred at room temperature for 48 h, at 
which time 20 mL of water was added.  Then, MeOH and triethylamine in the mixture 
were removed in vacuo.  To remove any remaining allolactobionic acid, existing as its 
triethylamine salt, the resulting aqueous solution was passed through an anion exchange 
column (10 mm x 20 mm) into a receiving beaker containing 1.0 mg of MEHQ.  
Resulting triethylamine was then removed in vacuo.  Cation exchange resin was added to 
the solution, stepwise, until no ninhydrin reactive material was left (by thin layer 
chromatography).  The mixture was then filtered and freeze-dried.  Removal of MEHQ in 
the freeze-dried product was accomplished by dissolving the material in a minimum 
amount of MeOH, which was then added to cold acetone to precipitate ALAEMA.  
Following filtration and drying, ALAEMA (0.82 g, 59% yield) was obtained.  The purity 
and structure of the final product were confirmed by 1H NMR, 13C NMR and mass 
spectrometry (Figure III-4, 5).  Anal. Calcd for C18H32N2O12+3/2H2O: C, 43.63; H, 7.12; 
N, 5.65. Found: C, 43.54; H, 6.51; N, 5.43%. 
 
6-α-D-Mannopyranosyl-D-gluconamidoethyl methacrylamide (MGAEMA) 
To the solution of 1.0 g of 6-O-α-D-mannopyranosyl-D-gluconolactone (2.94 
mmol) in 3.0 mL of MeOH, were added AEMA (0.58 g, 3.53 mmol) and 1.0 mg MEHQ 
in 2.0 mL of MeOH and1.0 mL of triethylamine.  The mixture was stirred at room 
temperature for 48 h, at which time 20 mL of water was added.  Then, MeOH and 
triethylamine in the mixture were removed in vacuo.  To remove any remaining 
disaccharide acid, existing as its triethylamine salt, the resulting aqueous solution was 
passed through an anion exchange column (10 mm x 20 mm) into a receiving beaker 
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containing 1.0 mg of MEHQ.  Resulting triethylamine was then removed in vacuo.  
Cation exchange resin was added to the solution, stepwise, until no ninhydrin reactive 
material was left (by thin layer chromatography).  The mixture was then filtered and 
freeze-dried.  Removal of MEHQ in the freeze-dried product was accomplished by 
dissolving the material in a minimum amount of MeOH, which was then added to cold 
acetone to precipitate MGAEMA.  Following filtration and drying, MGAEMA (0.89 g, 
64% yield) was obtained.  The purity and structure of the final product were confirmed 
by 1H NMR, 13C NMR and mass spectrometry (Figure III-6, 7).  Anal. Calcd for 
C18H32N2O12+3/2H2O: C, 43.63; H, 7.12; N, 5.65. Found: C, 43.84; H, 7.03; N, 5.43% 
 
2-Melibionamidoethyl methacrylamide (MAEMA) 
To the solution of 1.0 g of melibionolactone (2.94 mmol) in 3.0 mL of MeOH, 
were added AEMA (0.58 g, 3.53 mmol) and 1.0 mg MEHQ in 2.0 mL of MeOH and1.0 
mL of triethylamine.  The mixture was stirred at room temperature for 48 h, at which 
time 20 mL of water was added.  Then, MeOH and triethylamine in the mixture were 
removed in vacuo.  To remove any remaining melibionic acid, existing as its 
triethylamine salt, the resulting aqueous solution was passed through an anion exchange 
column (10 mm x 20 mm) into a receiving beaker containing 1.0 mg of MEHQ.  
Resulting triethylamine was then removed in vacuo.  Cation exchange resin was added to 
the solution, stepwise, until no ninhydrin reactive material was left (by thin layer 
chromatography).  The mixture was then filtered and freeze-dried.  Removal of MEHQ in 
the freeze-dried product was accomplished by dissolving the material in a minimum 
amount of MeOH, which was then added to cold acetone to precipitate MAEMA.  
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Following filtration and drying, MAEMA (0.94 g, 68% yield) was obtained.  The purity 
and structure of the final product were confirmed by 1H NMR, 13C NMR and mass 
spectrometry (Figure III-8, 9).  Anal. Calcd for C18H32N2O12+3/2H2O: C, 43.63; H, 7.12; 
N, 5.65. Found: C, 43.19; H, 6.77; N, 5.37% 
 
Kinetic experiment for the RAFT tri-component polymerization of GAEMA    
To a 5 ml Schlenk tube equipped with a septum, was added 2.4 mL water 
containing 128.5 mg of GAEMA (419.5 µmol), 10.3 mg AEMA·HCl (62.9 µmol) and 
166 µL of HEAA (1615.1 µmol) thus producing  a monomers molar ratio of 20:3:77, 
respectively.  To the solution were then sequentially added 0.3 mL dimethylformamide 
(DMF) containing 3.1 mg of (4-cyanopentanoic acid)-4-dithiobenzoate [11 µmol, chain 
transfer agent (CTA)], and 0.3 mL DMF containing 1.5 mg 4,4′-azobis (4-cyanovaleric 
acid) (5.4 µmol, initiator).  The resulting molar ratio of [M]0:[CTA]:[Initiator] was 
380:2:1, where [M]0 is the initial total monomers concentration.  The solution was then 
degassed with 3 freeze–evacuate–thaw cycles and the Schlenk tube transferred to a water 
bath at 70°C.  At each time point of the copolymerization (2, 4, 7, 11, 24, and 35 h), 200 
µL of the solution were withdrawn with an argon-purged gas tight syringe and 
precipitated in 10 mL of cold acetone containing 1.0 mg of MEHQ.  The precipitates 
were dried in vacuo and prepared for gel permeation chromatography (GPC) and NMR 
analysis, as noted below.  The conversion rates of GAEMA were determined by 
comparing the proton signal changes from both H-2 (δ 4.30-4.40) and H-3 (δ 4.05-4.15) 
(Figure III-10).  
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One-step tri-component RAFT-based copolymerization (see Scheme III-4)   
To a 1 ml Schlenk tube equipped with a septum, was added 0.4 mL water 
containing 21.4 mg of GAEMA or 32.8 mg of disaccharide monomers (70.0 µmol, Table 
III-1), 1.7 mg AEMA (10.5 µmol) and 27.5 µL HEAA (270 µmol), thus having a 
monomer molar ratio of 20:3:77, respectively.  To the monomer solution were then 
sequentially added 50 µL DMF containing 0.53 mg of (4-cyanopentanoic acid)-4-
dithiobenzoate (1.9 µmol) and another 50 µL DMF containing 250 µg of 4,4′-azobis-(4-
cyanovaleric acid) (0.9 µmol) resulting in a molar ratio of [M]0:[CTA]:[Initiator] to be 
380:2:1.  The mixture was degassed with 3 freeze–evacuate–thaw cycles and transferred 
to a water bath at 70°C for 24 h.  At this time, an aliquot of the solution (100 µL) was 
treated with 20 mL of ice cold acetone and the precipitated polymers were analyzed by 
GPC, as described below.  The remainder of the solutions were then dialyzed against 
deionized water (6 x 2L) over a period of 24 h (MWCO=3,500) and then lyophilized.  
The resultant statistical poly-methacrylamide/acrylamide (PMA) copolymers containing 
pendant glyconamides, 4-O-β-D-galactopyranosyl-D-gluconamide (lactobionamide), 6-O-
β-D-galactopyranosyl-D-gluconamide (allolactobionamide), 6-O-α-D-galactopyranosyl-D-
gluconamide (melibionamide) or 6-O-α-D-mannopyranosyl-D-gluconamide, were 
obtained.  For ease of discussion, they are abbreviated as PMA-GAEMA, PMA-LAEMA, 
PMA-ALAEMA, PMA-MAEMA, and PMA-MGAEMA, respectively (Table III-1). 
 
Synthesis of PMA-ALAEMA with different degree of polymerization (DP)   
To test the ability of the tri-component RAFT reaction to produce varied 
copolymer lengths, reactions with varied concentrations of CTA and initiator were 
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performed (Table III-2).  A parallel reaction without using any CTA was performed, as 
well.  For all reactions, the amounts of monomers used and the reaction procedures were 
exactly the same as described in the section above.  The synthesized PMA-ALAEMA 
glycopolymers with different DPs were characterized on GPC. 
 
Post-modification of glycopolymers with fluorophores  
Glycopolymers (5.0 mg) containing ~0.9 µmole of primary amine functional 
groups were individually dissolved in 0.9 mL phosphate buffered saline (PBS, 0.1 M 
sodium phosphate, 0.15 M NaCl, pH 7.5).  To each solution, with rapid stirring, was 
slowly added 100 µL DMF containing 0.6 mg of carboxyfluorescein succinimidyl ester 
(1.3 µmol), or 1.1 mg of Texas Red-X succinimidyl ester (1.3 µmol).  The reactions were 
gently stirred for 16 h in the dark and then dialyzed against 6 x 2 L distilled deionized 
water over a period of 24 h (MWCO=3,500).  Following lyophilization, a colored 
flocculent product was obtained for each glycopolymer.  In some experiments, to confirm 
the completeness of reaction between the primary amines and fluorophore succinimidyl 
esters, purified labeled glycopolymers were retreated with an additional fluorophore 
reagent and the products tested for any increase in fluorescence. 
 
Binding tests of the synthetic glycopolymers with lectin coated agarose beads   
The lectin-binding specificities of the synthesized glycopolymers were first 
probed by testing with plant lectin-coated agarose beads.  As an example of the binding 
test protocol, a 50 µL suspension of GNL coated agarose beads, which binds α-mannose 
specifically, were washed three times with 1.5 mL PBS and resuspended in 0.5 mL PBS.  
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To the mixtures were added 3 µg of PMA-MGAEMA-Fluorescein or PMA-MAEMA-
Fluorescein, respectively.  Following a1h incubation in the dark at room temperature, the 
mixtures were each then washed three times with 1.5 mL PBS.  In a parallel competitive 
binding test, the GNL agarose beads were pre-incubated with 1.0 mg of non-fluorescent 
PMA-MAEMA or PMA-MGAEMA for 20 min before the addition of 3 µg of PMA-
MGAEMA-Fluorescein.  The final beads pellets from the binding tests were each 
resuspended in 1.0 mL PBS, 4 µL aliquots were then subjected to fluorescence 
microscopy (Olympus BX43, FITC filter used), and 100 µL aliquots were taken for 
measurements of their fluorescence intensities (λex/λem = 490/520 nm, slit width=10 
nm) on a microplate reader (BioTek Synergy Mx). Employing the same protocol, 
Marasmius oreades agglutinin-coated lectin beads were used to confirm the binding with 
α-galactoside containing copolymers, while peanut agglutinin lectin beads were used to 
probe for β-galactoside binding. 
 
Lectin-mediated bacterial binding with fluorescent glycopolymers   
S. aureus ATCC 25923 and P. aeruginosa ATCC 39018 were separately cultured 
on either mannitol salt or trypticase soy agar for 24 h.  The colonies were then lifted and 
suspended in 20 mL of binding solution (155 mM NaCl, 1 mM CaCl2, and 1% bovine 
serum albumin) to attain a bacterial suspension with an optical density of 1 at 600nm.  
For each binding experiment, 100 µg of fluorescent glycopolymers, dissolved in 100 µL 
sodium phosphate buffer (0.3 M, pH=7.4), were then added to 1.0 mL of a bacteria 
suspension to be tested, respectively, and incubated for 2 h in the dark at 35°C with 
gentle shaking.  Specifically, S. aureus was treated with PMA-ALAEMA-Fluorescein, 
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while PMA-MAEMA-Texas Red was employed for binding to P. aeruginosa.  In 
negative control experiments, either PMA-GAEMA-Fluorescein or PMA-GAEMA-
Texas Red was used in the incubation.  Following incubation, all bacteria-glycopolymer 
mixtures were then centrifuged (8,000 X g, 10 min) and the pellets were washed three 
times with 1.2 mL saline (155 mM NaCl containing 1 mM CaCl2).  The final pellets were 
then resuspended in 20 µL of saline, and 4 µL aliquots were taken for analysis by 
fluorescence microscopy.  The green and red fluorescence-labeled bacteria in each photo 
representing one or several glycopolymer-binding S. aureus and P. aeruginosa 
respectively were quantified by the software cellSens Dimension (Olympus).   
Employing the same protocol described above, S. aureus ATCC 25923 was also 
separately tested with 100 µg of fluorescein-labeled PMA-LAEMA, PMA-ALAEMA, 
PMA-MAEMA, and PMA-GAEMA in order to compare their carbohydrate-binding 
specificities. The bacteria pellets after three washings were resuspended in 100 µL PBS 
(pH=8), and the fluorescence intensities were measured on the microplate reader. All 
binding experiments were performed in triplicate.    
 
Analysis 
1H and 13C NMR spectra of samples dissolved in D2O were recorded on a Bruker 
Avance 800 MHz spectrometer.  1H and 13C spectra were recorded at 800.14 and 201.19 
MHz, respectively.  Glycomonomers, dissolved in MeOH/water 50:50 (v/v) were 
subjected to direct electrospray mass spectrometry analyses, utilizing a Thermo Scientific 
LTQ Orbitrap XL hybrid Fourier transform mass spectrometer.  Molecular weights (Mw, 
Mn) and the dispersity (Mw/Mn) of the glycopolymers were derived against a calibration 
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curve from polyethylene glycol standards (MW: 200-1,200,000 g/mol) using a Waters 
Alliance HPLC system equipped with a refractive index detector (Waters e2695, 2414) 
and TOSOH TSK-GEL G4000 PWxl and a TSK-GEL G4000 SW GPC columns using 
0.1M Tris/0.1M sodium chloride buffer (pH=7) as eluent at a flow rate of 0.6 mL/min.  
The actual concentrations of primary amine functional groups within the glycopolymers 
were quantified with Orange II according to a published protocol (25).  Total 
carbohydrate content of the synthesized glycopolymers was analyzed according to a 
published method (26).  Elemental analysis was performed by Galbraith Laboratories, 
Knoxville, TN.  
 
Results and discussion  
Synthesis of glycomonomers 
            In order to provide for desired conformations of pendant sugars presented by 
glycopolymers to plant and bacterial lectins, we have chosen disaccharides lactose, 
melibiose, allolactose and α-D-mannopyranosyl-(1→6)-D-glucose as the specific 
glycoside sources.  All disaccharides were then oxidized with iodine and dehydrated to 
their respective lactones.  These disaccharide lactones, and gluconolactone, were then 
reacted with the primary amine functional group on AEMA to produce a group of 
glycomonomers, listed in Table III-1.  While GAEMA and LAEMA have been 
previously reported (4,19), glycomonomers ALAEMA, MAEMA, and MGAEMA, are 
novel glycosynthons designed to provide α-galactoside, β-galactoside and α-mannoside, 
respectively, as the pendant carbohydrate residues.  In contrast to the report on the 
preparation of LAEMA (19), we initially obtained varied amounts of the product which 
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was also of an unsatisfactory purity.  A modified purification procedure was thus 
developed for the disaccharide lactone, which uses cation and anion-exchange resins, 
sequentially, to remove unreacted AEMA and disaccharide acids, respectively, resulting 
in less variable yields of 59% to 68% (Table III-1).  Characterizations performed by 
NMR spectroscopy, mass spectrometry, and elemental analysis confirmed the high 
purities of the products.  1H NMR spectroscopy of the glycomonomers also confirmed the 
correct conformations at the anomeric carbons in allolactose and α-D-mannopyranosyl-
(1→6)-D-glucopyranose. 
 
Kinetic experiment for the RAFT tri-component polymerization of GAEMA   
GPC traces of the PMA-GAEMA copolymers at different time points indicate that 
the RAFT-based polymerization was well-controlled, as evidenced by the consecutive 
low dispersities (<1.3) of the products and of the steady evolution of the Mn (Figure III-
11).  As expected, the examination of developing copolymers by 1H NMR indicated that 
the consumption of GAEMA and HEAA monomers in the reaction proceeded at different 
rates with GAEMA being consumed somewhat faster.  This observation is a focus of an 
ongoing investigation.  Overall, > 95% of the conversion was completed in the first 24 h 
(Figure III-11b).  
 
RAFT-based synthesis of glycopolymers   
In this study, a facile one-step RAFT-mediated tri-component copolymerization 
strategy was employed.  Compared to the bi-block or tri-block glycopolymers prepared 
through stepped RAFT-controlled polymerizations (15,19,27), this one-step reaction 
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should provide for a more random distribution of the glycomonomers in the products, as 
seen in naturally occurring glycoprotein, mucous glycoproteins and glycolipids.  In this 
work, we prepared glycopolymers that contain 20 mol% of glycomonomer, HEAA (77 
mol% on polymer) as spacer, and AEMA (3 mol%) as targets for post-modifications with 
fluorophores and then employed them in a lectin-binding study similar to that reported by 
Bovin in the use of early neoglycoconjugates (28).  With the use of RAFT reactions, 
synthesized glycopolymers with different pendant sugars on the gluconamide linker 
(Table III-1) demonstrated low dispersities (≤1.32), very similar GPC traces and Mn 
(Figure III-12, Table III-3).  As can be seen in Figure III-12, when plotted against the 
elution profiles of these glycopolymers, only PMA-GAEMA displayed a smaller Mn due 
to the absence of a pendant pyranose.  For all glycopolymers, these results demonstrate a 
high reproducibility of copolymerization and, following individual analysis of product 
components (i.e., carbohydrates and primary amine functional groups (Table III-3), it was 
determined that the ratio of incorporated monomers in the respective glycopolymers 
reflected the stoichiometric ratio of monomers employed in the initial RAFT reactions.  
In other words, the stoichiometry of components in RAFT reactions predictably defined 
the respective product composition.  Structural confirmation of the resultant 
glycopolymers was performed by 1H- and 13C-NMR (Figure III-13-16).  
That the pendant sugars are located on a gluconamide linker, is of special note, in 
that it results in formation of polymers that are more physiologically relevant because of 
the hydrophilic nature of the polysaccharides chains on many natural glycoproteins. 
To test the ability of CTA to control the DPs and dispersity of the product 
copolymers, varied amounts of CTA (Table III-2) were employed in the polymerizations.  
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A class of PMA-ALAEMA polymers with determined DPs was prepared and they clearly 
showed that reactions with RAFT reagents produced polymers that possessed 
considerably lower dispersities than polymers prepared without any CTA in the reaction 
(Figure III-17). 
 
Post-modification of glycopolymers with fluorophores  
The reaction of primary amine functional groups with a variety of reactive 
fluorophores is a technique frequently employed in protein labeling.  This versatility was 
incorporated into our investigation by post-modifying the amine functional groups in our 
purified glycopolymers by separately reacting them with either activated succinimidyl 
esters of carboxyfluorescein or Texas Red-X fluorophores. 
After 16 h of reaction in PBS buffer, and 24 h dialysis against water, respective 
fluorescent polymers (i.e., PMA-MAEMA-Texas Red or PMA-GAEMA-Texas Red, and 
PMA-ALAEMA-Fluorescein or PMA-GAEMA-Fluorescein) were obtained, with no 
detectable degradation of the polymers, as determined by GPC analysis (data not shown).  
Compared to other labeling protocols applied to glycopolymers (2,19), this present 
method of post-modification is both simpler and amenable to choice of fluorescent label 
desired for different experimental designs.  In our opinion, most of the water-soluble 
amine-reactive fluorophores, biotins or quantum dots (22), should be suitable for labeling 
of these synthesized glycopolymers. 
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Binding of synthetic glycopolymers with plant lectin coated agarose beads  
In order to assess the lectin-binding specificities of the synthesized glycopolymers, 
each glycopolymer product was individually tested and confirmed with its corresponding 
lectin-coated agarose beads.  As an example, the binding results with α-mannose-specific 
lectin GNL are presented here.  Figure III-18a demonstrates the negligible binding of 
GNL beads with PMA-MAEMA-Fluorescein which contains α-galactose as the pendant 
sugar.  In contrast, the α-mannose-containing polymer PMA-MGAEMA-Fluorescein 
showed very strong binding (Figure III-18b).  To further validate the binding specificity 
with the synthesized glycopolymers, this binding was competitively inhibited when the 
GNL beads were pre-incubated with 1 mg of non-fluorescent PMA-MGAEMA (Figure 
III-18c), and, when pretreated with 1 mg of PMA-MAEMA, no such effects were 
observed (Figure III-18d).  The fluorescence intensities measured on the microplate 
reader (Figure III-19) were consistent with the observation by microscopy.  Similarly, the 
binding specificities of the three different galactose-containing glycopolymers were 
confirmed by employing agarose beads coated with either Marasmius oreades agglutinin 
or peanut agglutinin lectin and the respective competitive inhibition by the corresponding 
non-fluorescent glycopolymers (data not shown). 
 
Lectin-mediated binding of bacteria with fluorescent glycopolymers   
Having established the specific affinities of the synthetic glycopolymers towards 
plant lectin-coated agarose beads, application of these polymers with clinically relevant 
bacterial strains was performed.  The well-studied α-galactose-binding P. aeruginosa 
lectin PA-IL, which plays a crucial role in their opportunistic infections (29,30), was first 
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studied.  Ideal for this experiment, PMA-MAEMA-Texas Red, possessing α-galactose as 
the pendant sugar, was employed to test its binding ability with this organism.  As a 
negative control, PMA-GAEMA-Texas Red, lacking the pendant α-galactose group, was 
used.  In a parallel experiment, employing the same protocol, PMA-ALAEMA-
Fluorescein possessing β-galactose residues was tested for the recognition of S. aureus, 
with PMA-GAEMA-Fluorescein used as a negative control.  In three sets of repeated 
experiments, specific and dramatic binding of the respective glycopolymers between the 
bacteria and pendant sugars was observed by fluorescence microscopy (Figure III-20) 
when compared with the negative controls which demonstrated an occasional occurrence 
of non-specific binding (Figure III-21).  The weak non-specific binding with the negative 
controls could be due to associations between a few bacteria and the glycopolymer 
fluorophores, or possibly some traces unreacted primary amine functional groups 
remaining on the glycopolymer.  The latter hypothesis has been tested by subjecting the 
fluorescent glycopolymers to a second round of the fluorescent labeling.  However, no 
further increase in fluorescence was noted, nor did this retreatment affect the small 
amount of the non-specific binding to the bacteria.  
In another experiment where different fluorescein-labeled glycopolymers were 
used to test the carbohydrate-binding specificity of S. aureus ATCC 25923, PMA-
ALAEMA and PMA-LAEMA, both possessing β-D-galactose as the pendant sugar, 
showed dramatically higher binding than either PMA-MAEMA, which possesses α-D-
galactose, or the negative control PMA-GAEMA. These results suggest that this strain of 
S. aureus has a binding preference for β-D-galactose (Figure III-22). 
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    Understanding that the outcome of synthesizing a group of tri-component 
polymers would produce statistical polymers, we anticipated the possibility of 
glycopolymer molecules that would not have incorporated any AEMA monomer and thus 
would not be fluorophore-labeled.  Thus, the presence of these unlabeled glycopolymers 
would then potentially act as binding competitors.  Although we did not attempt to 
determine the percentage of such species, considering the very low possibility of such 
polymers (4.7%, i.e., 0.97100≈0.04755), their competition effects in the present 
experiments were not considered to be significant. Also, based on statistical results, the 
majority of the synthetic copolymers (~87%) possess 1-5 AEMA monomers (shown in 
Table III-4), which is acceptable in the lectin-binding tests. 
As the binding between lectins and monosaccharides is generally very weak, 
strong interactions most often require multivalency of the sugars (3,31).  As the 
fluorescent-labeled glycopolymers produced in this investigation possess such 
multivalency (14-20 pendant carbohydrate residues per polymer), and strong associations 
are observed in our studies on both lectin beads and bacteria, these results suggest that 
these synthetic fluorescent glycopolymers could have application to many other 
carbohydrate-binding studies.  
Some studies suggest that the length of the linker sugar may affect the binding 
affinities of the glycopolymers (32,33).  In this present study, synthesis of disaccharides 
to be converted to lactones employed glucose as the only carbohydrate linker synthetic 
precursor.  Hence, when the resulting disaccharide lactones were formed and reacted with 
AEMA, a gluconamide linker was produced.  In light of these and earlier studies, our 
ongoing investigations include assessment of the effects of varying the length of the 
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linker, such as ribose (five-carbon sugar) or maltose (disaccharide), to which the pendant 
sugars are bound. 
 Lastly, interactions between lectins and carbohydrates often involve more than 
one glyco-epitope (34).  Any disaccharides or oligosaccharides of interest, in theory, can 
be conjugated onto a linear polymer following this protocol.  In addition, by varying the 
polymer length, the ratios of glycomonomers or labeling fluorophores (33,35), improved 
binding results might be achieved.  Furthermore, with the combination of different 
fluorophores and sugars, it’s now possible to accomplish the binding assays of multiple 
carbohydrates or crosslink different lectins all in one test.  The flexibility of this method 
also allows for optimization of desired glycopolymer products for lectins, antibodies, or 
other carbohydrate-binding structures pertinent to particular glycobiology interests.   
 
Conclusions 
A class of tri-component statistical glycopolymers was successfully prepared using 
RAFT-based one-step polymerizations.  Well-controlled reactions with good 
reproducibility yielded polymers with low dispersities and consistent compositions.  
Polymers with different degrees of polymerization and pendant sugars were synthesized.  
Each synthetic glycopolymer contained primary amine functional groups suitable for a 
variety of labels that can be attached via mild coupling chemistries, when needed.  To 
demonstrate this, both fluorescein and Texas Red-X were used to convert the synthetic 
glycopolymers into excellent reporters of specific lectins immobilized on agarose beads 
or expressed on surface of two clinically relevant bacteria.  The bacterial binding results 
illustrated our glycopolymers’ potential for clinically relevant applications.  Additional 
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investigations are merited to optimize the binding capacities of the desired synthetic 
glycopolymers for specific purposes, such as by varying the polymer length, monomer 
ratios, linker structures, and choice and content of labels.  In conclusion, the method 
presented here offers a relatively straightforward and dependable way to prepare 
heterofunctionalized linear glycopolymers for a variety of different research aims 
involving carbohydrate-protein specific interactions.  
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Table III-1. Synthesized glycomonomers, glycopolymers and their abbreviations. 
a PMA stands for poly-methacrylamide/acrylamide 
    
 
 
 
 
 
 
 
Glycomonomer (yield) 
           
Abbreviations 
 
Glycomonomers 
 
 
 
Glycopolymers 
2-Gluconamidoethyl methacrylamide (98%) GAEMA PMAa- GAEMA 
2-Lactobionamidoethyl methacrylamide (65%) LAEMA PMA-LAEMA 
2-Allolactobionamidoethyl methacrylamide (59%) ALAEMA PMA-ALAEMA 
2-Melibionamidoethyl methacrylamide (68%) MAEMA PMA-MAEMA 
6-O-α-D-mannopyranosyl-D-gluconamidoethyl methacrylamide (64%) MGAEMA PMA-MGAEMA 
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Table III-2.  Parameters of reactions synthesizing PMA-ALAEMA with different 
DP      
                 
Copolymerizations 
Amount of 
CTA used, /mg 
Amount of 
initiator used, /mg 
Target DP, 
[M]0/[CTA] 
Reaction yield 
after dialysis, % 
Actual DPs a 
#1 1.00 0.25 97 45 26 
#2 0.53 0.25 190 78 101 
#3 0.25 0.25 386 81 260 
#4 0 2.00 NA 98 382 
a calculated by Mn/(0.77MWHEAA+0.2MWALAEMA+0.03MWAEMA) 
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Table III-3.  Summary of the synthetic parameters and actual compositions of the 
RAFT glycopolymers 
  a calculated by Mn/(0.77MWHEAA+0.2MWglycomonomer+0.03MWAEMA).  Considering actual 
DP and contents of each monomer in the polymers, these statistical copolymers are 
denoted as P(GAEMA-stat-AEMA2.4-stat-HEAA); P(MAEMA20.0-stat-AEMA3.1-stat-
HEAA71.9); P(LAEMA19.0-stat-AEMA3.2-stat-HEAA76.8); P(ALAEMA18.0-stat-AEMA3.0-
stat-HEAA80); P(MGAEMA14.1-stat-AEMA3.0-stat-HEAA70.9).  
  
Glycopolymer 
Pendant 
sugar(linkage) 
Mn, GPC  
g/mol 
DP a Mw/Mn 
Actual content of 
glycomonomers, 
mol% 
Actual content of 
primary amine, 
mol% 
Reaction yield 
after dialysis, 
% 
PMA-GAEMA None 13696 89 1.32 NA 2.7 70 
PMA-MAEMA α-galactose (1→6) 17684 95 1.30 21 3.3 74 
PMA-LAEMA β-galactose (1→4) 18431 99 1.26 19 3.2 76 
PMA-ALAEMA β-galactose (1→6) 18943 101 1.21 18 3.0 78 
PMA-MGAEMA α-mannose (1→6) 16498 88 1.31 16 3.4 68 
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Table III-4. Statistical possibilities for copolymers to contain a certain number of 
AEMA 
 
 
 
 
 
   
Number of AEMA in each 
copolymer (100mer) 
Possibilities 
0 4.7 
1 14.7 
2 22.5 
3 22.75 
4 17.1 
5 10.1 
6 5 
7 2.06 
8 0.74 
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Figure III-1. Chemical structures of some key reagents used. 
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Figure III-2. Assigned 1H- (a) and 13C-NMR (b) spectra (D2O) for LAEMA. 
 
1H NMR (800 MHz, D2O): δ (ppm) 5.70 (s, 1H, H-17A), 5.46 (s, 1H, H-17B), 4.56 (d, 
J7,8 =7.8, 1H, H-7), 4.41 (d, J2,3 =2.6, 1H, H-2), 4.19 (m, J3,4 =4.2, 1H, H-3), 3.99 (m, 
J4,5=6.4, 1H, H-4), 3.96-3.92 (m, 2H, H-5, H-10), 3.87 (m, 1H, H-6B), 3.77 (m, 1H, H-
6A), 3.79-3.76 (m, 2H, H-12), 3.73 (m, 1H, H-11), 3.68 (dd, J9,10 = 3.4, 1H, H-9), 3.58 
(dd, J8,9 = 9.9, 1H, H-8), 3.48-3.41 (m, 4H, H-13, H-14), 1.93 (s, 3H, H-15).   
13C NMR (201 MHz, D2O): δ (ppm) 177.53 (C-1), 174.95 (C-18), 141.88 (C-16), 124.04 
(C-17), 106.34 (C-7), 83.95 (C-4), 78.21 (C-11), 75.35 (C-9), 75.22 (C-2), 74.29 (C-5), 
73.90 (C-8), 73.27 (C-3), 71.46 (C-10), 64.83 (C-6), 63.89 (C-12), 41.82 (C-13), 41.29 
(C-14), 20.49 (C-15).   
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Figure III-3. Mass spectrum of LAEMA by ESI-MS (in methanol: water 50:50).  
Calculated m/z for C18H32O12N2+Na
+, 491.18475; found m/z 491.19327. 
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Figure III-4. Assigned 1H- (a) and 13C-NMR (b) spectra (D2O) for ALAEMA. 
 
1H NMR (800 MHz, D2O): δ (ppm) 5.71 (s, 1H, H-17A), 5.47 (s, 1H, H-17B), 4.44 (d, 
J7,8 =7.8, 1H, H-7), 4.32 (d, J2,3 =3.5, 1H, H-2), 4.13-4.15 (m, J5,6A =11, J5,6B =2.6, 1H, H-
5), 4.09 (m, J3,4 =3.5, 1H, H-3), 3.93 (m, 1H, H-10), 3.92 (m, 1H, H-4), 3.83-3.81 (m, 
2H, H-6), 3.80-3.75 (m, 2H, H-12), 3.71 (m, J11,12A =4.2, J11,12B =7.9, 1H, H-11), 3.67(dd, 
J9,10 = 3.3, 1H, H-9), 3.58 (dd, J8,9 = 9.9, 1H, H-8), 3.48-3.41 (m, 4H, H-13, H-14), 1.93 
(s, 3H, H-15).   
13C NMR (201 MHz, D2O): δ (ppm) 177.57 (C-1), 174.96 (C-18), 141.82 (C-16), 124.06 
(C-17), 106.28 (C-7), 77.99 (C-11), 76.00 (C-2), 75.47 (C-9), 74.78 (C-6), 73.93 (C-5), 
73.72 (C-8), 73.17 (C-3), 72.77 (C-4), 71.48 (C-10), 63.84 (C-12), 41.73 (C-13), 41.27 
(C-14), 20.45 (C-15).   
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Figure III-5. Mass spectrum of ALAEMA by ESI-MS (in methanol: water 50:50).  
Calculated m/z for C18H32O12N2+Na
+, 491.18475; observed m/z 491.19305. 
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Figure III-6. Assigned 1H- (a) and 13C-NMR (b) spectra (D2O) for MGAEMA. 
 
1H NMR (800 MHz, D2O): δ (ppm) 5.71 (s, 1H, H-17A), 5.47 (s, 1H, H-17B), 4.90 (d, 
J7,8 =1.6, 1H, H-7), 4.31 (d, J2,3 =3.5, 1H, H-2), 4.10 (m, J3,4 =3.2, 1H, H-3), 4.00 (m, J8,9 
=3.3, 1H, H-8), 3.92-3.85 (m, 4H, H-5, H-12B, H-6B, H-9), 3.82 (dd, J4,5 =7.7, 1H, H-4), 
3.85-3.76 (m, 1H, H-12A), 3.73-3.69 (m, 2H, H-6A,H-11), 3.67 (m, J10,11 =9.9, 1H, H-
10), 3.47-3.42 (m, 4H, H-13, H-14), 1.93 (s, 3H, H-15).   
13C NMR (201 MHz, D2O): δ (ppm) 177.59 (C-1), 174.86 (C-18), 141.83 (C-16), 124.05 
(C-17), 102.61 (C-7), 76.15 (C-2), 75.53 (C-11), 74.73 (C-4), 73.42 (C-9), 73.17 (C-3), 
72.82 (C-8), 72.04 (C-5), 70.81 (C-6), 69.62 (C-10), 63.79 (C-12), 41.74 (C-13), 41.31 
(C-14), 20.47 (C-15).   
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Figure III-7. Mass spectrum of MGAEMA by ESI-MS (in methanol: water 50:50).  
Calculated m/z for C18H32O12N2+Na
+, 491.18475; found m/z 491.19501. 
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Figure III-8. Assigned 1H- (a) and 13C-NMR (b) spectra (D2O) for MAEMA. 
 
1H NMR (800 MHz, D2O): δ (ppm) 5.70 (s, 1H, H-17A), 5.46 (s, 1H, H-17B), 4.98 (d, 
J7,8 =3.6, 1H, H-7), 4.32 (d, J2,3 =3.7, 1H, H-2), 4.10 (m, J3,4 =3.4, 1H, H-3), 4.01-3.98 
(m, 2H, H-10, H-11), 3.94-3.88 (m, 3H, H-9, H-6B, H-10), 3.85-3.81 (m, 2H, H-4, H-5), 
3.76-3.73 (m, 2H, H-12), 3.68 (m, 1H, H-6A), 3.41-3.47 (m, 4H, H-13, H-14), 1.93 (s, 
3H, H-15).   
13C NMR (201 MHz, D2O): δ (ppm) 177.64 (C-1), 174.97 (C-18), 141.84 (C-16), 124.06 
(C-17), 101.21 (C-7), 76.09 (C-2), 74.64 (C-5), 73.79 (C-10), 73.30 (C-3), 72.38 (C-8), 
72.29 (C-9), 72.11 (C-11), 71.38 (C-4), 71.17 (C-6), 64.00 (C-12), 41.73 (C-13), 41.33 
(C-14), 20.49 (C-15).   
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Figure III-9. Mass spectrum of MAEMA by ESI-MS (in methanol: water 50:50).  
Calculated m/z for C18H32O12N2+Na
+, 491.18475; found m/z 491.19424. 
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Figure III-10. Assigned 1H- (a) and 13C-NMR (b) spectra (D2O) for PMA-GAEMA 
glycopolymer.  
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Figure III-11. Kinetic study for the RAFT polymerization of PMA-GAEMA.  (a) Gel 
permeation chromatography traces of the copolymers indicating steady evolution of the 
copolymers with time.  (b) Mn dispersities of the glycopolymers over time. 
([M]0:[CTA]:[Initiator]=380:2:1; [M]0=0.7 M; solvent, H2O/DMF=4:1) 
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Figure III-12. Gel permeation chromatography traces of RAFT-based 
glycopolymers. ([M]0:[CTA]:[Initiator]=380:2:1; [M]0=0.7 M; solvent, H2O/DMF=4:1) 
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Figure III-13. Assigned 1H- (a) and 13C-NMR (b) spectra (D2O) for PMA-ALAEMA. 
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Figure III-14. Assigned 1H- (a) and 13C-NMR (b) spectra (D2O) for PMA-LAEMA 
glycopolymer. 
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Figure III-15. Assigned 1H- (a) and 13C-NMR (b) spectra (D2O) for PMA-MAEMA 
glycopolymer. 
 
85 
 
 
Figure III-16. Assigned 1H- (a) and 13C-NMR (b) spectra (D2O) for PMA-MGAEMA 
glycopolymer. 
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Figure III-17. Gel permeation chromatography traces of PMA-ALAEMA with 
different DPs from copolymerizations using different amounts of chain transfer 
agent ([M]0=0.7 M; solvent, H2O/DMF=4:1) 
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Figure III-18. Galanthus Nivalis lectin (GNL) coated agarose beads bind α-D-
mannoside containing glycopolymers, but not those possessing α-D-galactoside.  
PMA-MAEMA-Fluorescein (3µg) showed only a weak non-specific binding with GNL 
(a), in contrast to the strong binding between PMA-MGAEMA-Fluorescein and the beads 
(b).  Pre-incubation of the beads with 1.0 mg of non-fluorescent PMA-MGAEMA for 20 
min before adding 3µg of PMA-MGAEMA-Fluorescein dramatically reduced the binding 
of the latter (c), but the pre-incubation with 1.0 mg of PMA-MAEMA didn’t show any 
competitive inhibition effects (d).  Scale bar = 100 µm. 
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Figure III-19. Galanthus Nivalis lectin coated agarose beads bind with α-mannose 
containing glycopolymers, but not with those containing α-galactose.  The measured 
fluorescence intensities (λex/λem = 490/520 nm, slit width=10 nm) of the samples a-d in 
Figure 5 were consistent with the observation by fluorescence microscopy.    
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Figure III-20. Representative lectin-mediated binding of bacteria to synthetic 
fluorescent glycopolymers.  Fluorescence microscopy of a mixture of the binding tests: 
P. aeruginosa with PMA-MAEMA-Texas Red (100 µg) and S. aureus with PMA-
ALAEMA-Fluorescein (100 µg).  Scale bar = 100 µm. 
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Figure III-21. Quantification of the binding bacteria observed in each sample using 
the software cellSens Dimension.  The final bacteria suspensions from the binding tests 
were subject to fluorescence microscopy analysis with a magnification of 100X.  The 
green and red fluorescence-labeled bacteria in each photograph representing one or 
several glycopolymer-binding S. aureus and P. aeruginosa respectively were analyzed 
and quantified separately.  For both bacteria, glycopolymers containing corresponding 
pendant sugars (positives) showed dramatically stronger binding compared with 
fluorescent PMA-GAEMA (negative controls).  
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Figure III-22. S. aureus ATCC 25923 showed binding specificity towards 
glycopolymers containing β-galactose as the pendant sugar.  Different fluorescent 
glycopolymers (100 µg) were used in corresponding binding test, and 100 µL of the final 
bacteria suspensions in PBS were used to measure their fluorescence intensities on the 
microplate reader (λex/λem = 490/520 nm, slit width=10 nm). 
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Schemes III-1. Synthesis of allolactose. 
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Schemes III-2. Synthesis of allolactonolactone. 
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Schemes III-3. Synthesis of ALAEMA.   
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Schemes III-4. Synthesis of fluorescent glycopolymers PMA-ALAEMA-Fluorescein 
containing β–galactoside as the pendant sugar. 
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Chapter IV. Monosaccharide-binding Profile of Pseudomonas 
aeruginosa Cystic Fibrosis Isolates Determined by testing with 
Multivalent Fluorescent Glycopolymers 
 
 
 
 
 
Abstract 
As a critical step of the persistent Pseudomonas aeruginosa infection in cystic 
fibrosis lungs, the bacteria use two lectins, LecA and LecB, together with other adhesins 
to bind specific carbohydrates on the surface of respiratory tract to start colonization.  
Blocking this binding with inhaled anti-adhesive carbohydrates offers a promising 
treatment for the infection.  Due to the diverse living microenvironment of the bacteria in 
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the patients’ lungs, P. aeruginosa isolated from cystic fibrosis often present varied colony 
morphologies and physiological phenotypes.  Therefore, we asked whether P. aeruginosa 
with different morphologies also have different carbohydrate-binding profiles, and what 
monosaccharides can be bound by the bacteria on a cellular level.  To answer these 
questions, a group of P. aeruginosa laboratory strains and clinical isolates with various 
morphologies were tested against a panel of fluorescent glycopolymers possessing 
distinct pendant monosaccharides.  As revealed by fluorescence microscopy, fluorimetry, 
flow cytometry and transmission electron microscopy, among the eight monosaccharides 
tested, α-D-galactose, β-D-N-acetylgalactosamine, and β-D-galactose-3-sulfate 
demonstrated strong binding with all the fifteen clinical isolates and three laboratory 
stains, and α-D-N-acetylneuraminic acid also showed weak binding with some of the P. 
aeruginosa tested.  However, within an isogenic bacterial population, only a small 
percentage (~1%) showed observable binding with the glycopolymers, revealing another 
phenotypic heterogeneity of the bacteria.  Therefore, the phenotypic diversity regarding 
monosaccharide-binding was not observed among different colony morphologies, but 
within isogenic populations.  
 
Introduction 
P. aeruginosa is a ubiquitous Gram-negative bacillus and a major opportunistic 
pathogen which is responsible for the chronic respiratory infection in a majority of the 
cystic fibrosis (CF) patients (1).  Within the respiratory tract of CF patients, P. 
aeruginosa normally first appear as motile and non-mucoid, which is the typical 
morphology of environmental isolates.  In the lungs, over time, due to the environmental 
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stresses  (2) and the formation of biofilms (3-5), the bacteria start to exhibit a wide range 
of phenotypic diversities.  These would include, among others, the appearance of 
different colony morphologies, elaboration of various virulence factors, and numerous 
physiological heterogeneities (6,7).  As a result, and with prolonged antibiotic usage, total 
eradication of the infection by any current antibiotics becomes very difficult (8).  To 
improve the outcome of antibiotic treatment in CF, a number of new strategies have 
evolved (9-11).  Among these, preliminary clinical trial with sugar inhalation therapy, 
designed to competitively inhibit the bacterial adhesion within the airway and possibly 
further eliminate the bacterial infection, has attracted much attention (12).  
P. aeruginosa binding with certain carbohydrate components of the respiratory 
mucins and host cell surface glycoproteins or glycolipids is a crucial step in their 
bacterial adhesion and colonization (13,14).  Therefore, inhibiting this binding by inhaled 
competitive carbohydrates offers a logical and possible therapeutic strategy.  Compared 
with the chemotherapy approaches, this anti-adhesion therapy is considered to be safer, 
more economical, and less possible to produce drug-resistant bacteria (10,15,16).  
Administration of simple sugars or their glycosides as therapeutic agents has shown 
encouraging results in vitro (17), in ex vivo (18), and in animal models (19).  A 
successful clinical trial and a case report using D-galactose and L-fucose in the inhalation 
therapy to treat CF or non-CF patients with P. aeruginosa infections have been 
published, as well (12,20).  However, our knowledge regarding the P. aeruginosa’s 
specific binding with monosaccharides, still needs to be explored further.  
P. aeruginosa express two soluble lectins, LecA and LecB (also known as PA-IL 
and PA-IIL), and several other adhesins, like pilin, flagellar cap protein, and flagellin 
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related to virulence factors of the bacteria (21-23).  LecA and LecB bind to α-D-galactose 
and α-L-fucose respectively on glycans (24).  Various disaccharides and oligosaccharides 
have also been identified as the binding targets of pilin and flagellar structures (22,25).  
Furthermore, a number of P. aeruginosa strains and clinical isolates have been 
demonstrated to bind mucin glycan components (13,26-28).  To our knowledge, there 
hasn’t been a thorough examination of the monosaccharide-binding profile of clinical P. 
aeruginosa isolates from CF patients to determine their primary binding targets on a 
cellular level.   
To assess bacterial and isolated bacterial proteins’ binding with carbohydrates, 
mucins and epithelial cells, a number of methods have been developed to include, 
amongst others, solid phase binding assays, glycoconjugate bindings tests, and glycan 
microarrays (29-31).  Among these methods, synthetic fluorescent glycopolymers have 
been successfully used in various sugar-lectin interaction studies (32,33), including 
bacterial carbohydrate-binding tests.  For instance, fluorescent glycopolymers containing 
Lewis antigens or blood group determinants showed different degrees of specific binding 
with several P. aeruginosa laboratory strains and clinical isolates (26).  Recently, our 
group also reported the preparation of a set of glycopolymers and their applications in 
lectin-mediated bacterial binding tests (34).s 
In this report, a panel of fluorescent polyacrylamide-based glycopolymers 
possessing multivalent monosaccharide side chains (PAA- Fluor-Sugars, structure shown 
in Figure IV-1) was chosen.  The non-reducing end of respiratory mucin glycans plays 
major role in the bacterial binding.  To represent these peripheral sugars that are mainly 
composed of L-fucose, D-galactose, D-N-acetylgalactosamine, and D-N-acetylneuraminic 
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acid, some of which are occasionally sulfated (35-37), nine different monosaccharides 
(Table I) were included in this study to test against a group of P. aeruginosa laboratory 
strains and clinical isolates with different colony morphologies (Table II).  We aimed to 
answer two questions regarding the carbohydrate-binding of P. aeruginosa in CF lungs: 
what monosaccharides P. aeruginosa can bind specifically on a cellular level, and 
whether different morphologies also have different carbohydrate-binding profiles.  
Answers to these questions will improve our understanding of the pathogenesis of P. 
aeruginosa infection in CF lungs and provide new perspective for the sugar inhalation 
anti-adhesion therapy being tested in clinic to treat bacterial infection.   
 
Materials and methods 
Materials  
Polyacrylamide glycopolymers possessing monosaccharide side chains (Table I) 
were purchased from GlycoTech (Gaithersburg, MD).  M9 minimum media, bovine 
serum albumin (BSA), sodium dodecyl sulfate, α-L-fucosidase (bovine kidney) were 
obtained from Sigma-Aldrich (St.  Louis, MO).  Gold-labeled anti-FITC antibody was 
purchased from Electron Microscopy Sciences (Hatfield, PA).  Agarose beads coated 
with Griffonia Simplicifolia lectin I, Erythrina Cristagalli lectin, soybean agglutinin, 
wheat germ agglutinin, and Aleuria aurantia lectin were purchased from Vector 
Laboratories (Burlingame, CA), and Limulus polyphemus lectin beads were from EY 
laboratories (San Mateo, CA). 
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Bacterial strains and growth conditions  
The P. aeruginosa laboratory strains were obtained from ATCC (Manassas, VA), 
and the clinical isolates were collected from patients admitted to University Hospital at 
University of Missouri, Columbia.  The bacterial colonies grown on tryptic soy agar with 
typical morphologies were selected and subcultured at 35°C in M9 minimum media for 
35 h or in TSB for 16 h (depending on whether culturable in minimum media, Table IV-
2). This study was approved by the University of Missouri's Health Sciences IRB. 
 
Binding tests of glycopolymers with lectin coated agarose beads   
To verify the binding specificities of the glycopolymers, a method previously 
published was employed herein (34).  As an example of this protocol, a slurry of agarose 
beads (100 µL) coated with soybean agglutinin, a GalNAc-binding lectin, was washed 
with PBS (3 x 1 mL), and then the pellets were resuspended in 0.5 mL PBS (with 1 mM 
CaCl2), to which were added 20 µL of sodium phosphate buffer (0.3 M, pH=7.4) 
containing 10 µg of PAA-α-GalNAc-Fluor.  The mixtures were incubated at 35°C for 1 h 
with gentle shaking, and then went through two repeated sets of centrifugation (4°C, 2, 
000 g for 3 min) and washing (1 mL PBS).  The final pellets were resuspended in 200 µL 
of PBS and observed by fluorescence microscopy. 
 
Bacterial binding tests 
The bacterial cultures were centrifuged at 4°C 9,000 x g for 15 min and the pellets 
were resuspended with filter-sterilized binding solution (155 mM NaCl, 1 mM CaCl2, 
0.5% BSA and 0.05% sodium dodecyl sulfate in distilled H2O) to attain suspensions with 
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an optical density of 1.0 at 600 nm.  The exact numbers of bacteria in the suspensions for 
each strain and isolate were determined by serial dilutions and plating of the suspensions.  
For each bacterial binding test, 18 µg of glycopolymers dissolved in 42 µL of sodium 
phosphate buffer (0.3 M, pH=7.4) were added to 1.0 mL of bacterial suspension.  
Bacterial suspensions without any glycopolymers and with conjugates containing no 
pendant sugars were used as negative control.  The mixtures were then incubated at 35°C 
in the dark for 2 h with gentle shaking, followed by two repeated sets of centrifugation 
(4°C, 9,000 x g, 15 min) and washing (1.2 mL of saline, 155 mM NaCl containing 1 mM 
CaCl2).  The resulting bacterial pellets were resuspended in 100 µL of PBS (pH=8).  The 
fluorescence intensities (λex/λem = 490/520 nm, slit width=10 nm) and optical densities 
at 600 nm of the suspensions were measured on a microplate reader (Synergy Mx, 
BioTek).  The fluorescence signals of the samples were normalized with their optical 
densities and the fluorescence intensities of the corresponding glycopolymers.  The 
bacterial suspensions were then subjected to fluorescence microscopy (10 x objective 
lens, Olympus BX43) analysis using the software cellSens Dimension (v1.7.1).  The 
fluorescence-labeled bacteria were detected and enumerated.  All bacterial binding 
experiments were performed in triplicate.    
 
Preparation of Reversible addition−fragmentation chain-transfer (RAFT) 
polymerization based PAA-α-Fuc-Fluor  
Synthesis of α-L-fucopyranosyl-(1→6)-D-glucose  
α-L-Fucopyranosyl-(1→6)-D-glucose was prepared according to a published 
method with some modifications (47).  Briefly, to a stirred solution of L-fucose (2.0 g) 
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and triethylamine (8.8 mL) in 60 mL of dry dimethylformamide (DMF), 8 mL of 
chlorotrimethylsilane were added at 0°C and the reaction was stirred at room temperature 
for 4 h.  Pentane (100 mL) and ice (40 mL) were then added and mixed; the organic layer 
was washed with cold water (40 mL x 3), dried over magnesium sulfate and evaporated 
to get per-O-trimethylsilyl-L-fucose (4.4 g, 80% yield).   
To a stirred solution of per-O-trimethylsilyl-L-fucose (2.7 g) in 20 mL of dry 
methylene chloride was added 0.86 mL of iodotrimethylsilane.  Following 20 min of 
stirring at room temperature, the mixture was added to a solution of 2.3 g of 6-hydroxy-
tetraacetyl-β-D-glucose (48) and 2, 6-di-tert-bytylpyridine (1.34 mL) in dry methylene 
chloride (40 mL).  After 5 h of stirring at room temperature, 60 mL of MeOH were added 
to the reaction and stirred for 20 min to remove the trimethylsilyl groups.  The mixture 
was then neutralized with ion exchange resin, filtered, and concentrated.  The partially 
acetylated products (1.61 g, 54% yield) were obtained by column chromatography 
(CHCl3: MeOH 8:1).  To 1.0 g of the partially acetylated disaccharide dissolved in 2 mL 
of CH2Cl2 were added 50 mL of MeOH and 1.0 mL of sodium methoxide solution 
(25 wt. % in methanol).  The mixture was stirred at room temperature for 20 min, 
neutralized with cation exchange resin, filtered, and evaporated to give the disaccharide 
α-L-fucopyranosyl-(1→6)-D-glucose with a quantitative yield. 
 
Synthesis of fucose-glucono-1,5-lactone 
  To a solution of α-L-fucopyranosyl-(1→6)-D-glucose (0.4 g) dissolved in 1.0 mL 
of water and 2.0 mL MeOH, were added an iodine solution in MeOH (0.6 g in 8 mL) at 
40°C.  A solution of 4% KOH in MeOH (15 mL, w/v) was then added dropwise for ~15 
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min, and the mixture was kept stirring until the iodine color completely disappeared.  The 
mixture was then cooled on ice and the precipitation was filtered.  The pellet was rinsed 
with small amount of cold MeOH and redissolved in 0.5 mL of water and re-precipitated 
in 25 mL of -20°C methanol.  The potassium salt was converted to the free acid form by 
passing the aqueous solution through a column containing 1 mL of cation-exchange resin.  
Lactone was formed by concentrating and drying the acid with repeated (5 times) 
evaporation of methanol and ethanol solution (0.33 g, 85% yield).  
 
Synthesis of glycomonomer 
To a solution of the disaccharide lactone (330 mg) in 2.0 mL of methanol were 
added 2.0 mL of methanol containing N-(2-aminoethyl) methacrylamide hydrochloride 
(197 mg) and hydroquinone monomethyl ether (MEHQ, 0.5 mg), and 0.3 mL of 
triethylamine.  Following 16 h of stirring at room temperature, 10 mL of water were 
added, and the methanol and triethylamine in the mixture were then removed from the 
mixture under vacuum.  The aqueous solution was passed through an anion exchange 
column into a receiving beaker containing 0.5 mg of MEHQ.  After the newly released 
triethylamine was removed in vacuo, the solution was passed through a cation exchange 
resin column and freeze-dried to give the glycomonomer: 6-O-α-L-fucopyranosyl-D-
gluconamidoethyl methacrylamide (424 mg, 92% yield).  ESI-MS (in methanol: water 
50:50): calculated m/z for C18H32O11N2+Na
+, 475.18983; observed m/z 475.19363. 
1H NMR (800 MHz, D2O): δ (ppm) 5.70 (s, 1H, H-17A), 5.46 (s, 1H, H-17B), 4.92 (d, 
J7,8 =3.2, 1H, H-7), 4.30 (d, J2,3 =3.2, 1H, H-2), 4.11 (m, 1H, H-10), 4.08 (m, 1H, H-4), 
3.94 (m, 1H, H-3), 3.90 (dd, 1H, H-8), 3.83 (m, 1H, H-5), 3.82-3.79 (m, 2H, H-6), 3.80-
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3.75 (m, 2H, H-12), 3.79 (m, 1H, H-11), 3.60 (dd, 1H, H-9), , 3.47-3.40 (m, 4H, H-13, H-
14), 1.92 (s, 3H, H-15), 1.22 (d, 3H, H-12). 13C NMR (200 MHz, D2O): δ (ppm) 177.59 
(C-1), 175.02 (C-18), 141.89 (C-16), 124.08 (C-17), 101.82 (C-7), 76.13 (C-2), 74.73 (C-
5), 73.24 (C-4), 72.85 (C-3), 73.44 (C-8), 71.87 (C-9), 77.15 (C-11), 69.59 (C-10), 58.86 
(C-6), 41.79 (C-13), 41.36 (C-14), 20.52 (C-15), 18.17 (C-12).   
 
Synthesis of glycopolymer PAA-α-Fuc 
To a 1 mL Schlenk tube was added 0.4 mL of water containing 31.6 mg of 6-O-α-
L-fucopyranosyl-D-gluconamidoethyl methacrylamide, 1.7 mg of N-(2-aminoethyl) 
methacrylamide and 27.5 µL of N-(2-hydroxyethyl) acrylamide.  To the mixture were 
then added 50 µL of DMF containing 0.53 mg of (4-cyanopentanoic acid)-4-
dithiobenzoate, and another 50 µL of DMF containing 250 µg of 4,4′-azobis-(4-
cyanovaleric acid) sequentially.  The solution was degassed with 3 freeze–evacuate–thaw 
cycles and kept in a water bath at 70°C for 24 h.  The solutions were then dialyzed against 
deionized water (6 x 2 L) for 24 h (MWCO=3,500) and lyophilized to attain the PAA-α-
Fuc (61 mg, 93.8% yield).  The glycopolymers’ dispersity (1.28) and degree of 
polymerization (95mer) were determined by GPC.  1H and 13C NMR spectra of the 
glycopolymer were shown in Figure IV-11, 12.  The post-modification of the synthesized 
glycopolymers and their characterizations were performed as described in Chapter III. 
 
Bacterial binding analysis by flow cytometry 
Further verification of the bacterial glycopolymer-binding employed a Beckman 
Coulter MoFlo XDP flow cytometer and Summit software (v5.3.1.12636) for data 
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acquisition and analyses.  For each bacterial sample, ~15,000 events were collected 
(debris and doublets excluded).   
 
Transmission electron microscopy 
To visualize the binding of P. aeruginosa with fluorescent glycopolymers, 
transmission electron microscopy was utilized.  Formvar carbon-coated nickel grids were 
floated on 25 µL of the resultant bacterial suspension from the binding tests for 10 min, 
air-dried, fixed with 4.0% paraformaldehyde in PBS for 30 min at room temperature.  
The grids were then washed on 40 µL of PBS (2 x 5 min) and once on PBS containing 
0.05% Tween-20 (v/v) and 1% BSA (PBS-Tween-BSA).  Grids were floated on a droplet 
of gold-labeled anti-FITC antibody at 1:20 in PBS-Tween-BSA at 4°C for 16 h, washed 
with PBS-Tween-BSA (6 x 5 min) and PBS (3 x 5 min).  Following post-fixation with 
2% glutaraldehyde in PBS (v/v) for 5 min, and washing on PBS (2 x 5 min) and distilled 
H2O (5 x 2 min), the grids were then examined with a JEOL 1400 transmission electron 
microscope without staining. 
 
Results and discussion 
Comparative binding of different fluorescent glycopolymers to P. aeruginosa isolates 
and strains 
The fluorescent glycopolymers (PAA-Sugars-Fluor) used in this study are listed 
in Table IV-1.  The lectin-binding specificities and capabilities of some of these polymers 
were confirmed by testing with corresponding lectin-coated agarose beads (Table IV-3).  
Those containing no pendant sugar but only aminoglucitol (spacer molecule) were used 
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as negative control.  Fifteen P. aeruginosa clinical isolates and three laboratory strains 
were tested, including five mucoid, four non-mucoid and nonmotile, and nine motile (see 
Table II).  After the incubation with glycopolymers and the following washings, the 
bacterial pellets were resuspended and subject to tests with fluorescence microscopy and 
fluorimetry.  BSA and sodium dodecyl sulfate were used in the binding tests to prevent 
non-specific bacterial binding with the polymers. 
Analysis by fluorescence microscopy revealed that among the eight 
monosaccharides, α-Gal, β-GalNAc and β-SO4-Gal showed relatively strong binding 
with all strains and isolates tested, and weaker binding was observed from α-Neu5Ac 
with some of the P. aeruginosa (Figure IV-2).  Under microscope, the difference between 
positive and negative binding bacterial samples was obvious (Figure IV-3).  With a 
higher magnification, it can be observed that the bacteria that demonstrate strong binding 
with the glycopolymers, in fact, only accounted for ~1% of the total population (Figure 
IV-4), suggesting a heterogeneous expression of lectins within an isogenic bacterial 
group.  To determine whether the low bacterial binding ratio was due to the washing and 
centrifugation during the tests, an aliquot of the bacterial suspensions after the incubation 
with glycopolymers was placed onto a microscope slide without washing and air-dried.  
After the unbound materials were gently rinsed off with phosphate buffered saline (PBS), 
the samples were analyzed by fluorescence microscopy.  As expected, a higher binding 
ratio (~2.5%) was observed, but the majority of the bacteria still didn’t show any 
observable binding (Figure IV-5).  This result demonstrates that some of the bacterial 
binding with glycopolymers was washed off during the two rounds of centrifugation and 
washing, but it doesn’t change the fact that a very small portion of the bacteria showed 
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much stronger binding than the rest of the population.  In another experiment where 
soybean agglutinin-coated agarose beads were tested with PAA-β-GalNAc-Fluor, more 
intense centrifugations (9,000 x g, 2 x 15 min) didn’t show a decreased binding compared 
with a less intense centrifugation (2,000 x g, 2 x 3 min) (data not shown), suggesting the 
lectin binding with the glycopolymer was able to stand the centrifugation at such a speed.  
Considering that only a very small percentage of the fluorescent glycopolymers remained 
in the sample after the binding tests (~0.1%, based on fluorescence intensities), this low 
binding ratio was very unlikely because the amount of polymers used in the tests was too 
low. 
Of the three binding monosaccharides, α-Gal is the binding target of LecA (24), 
and β-GalNAc and α-Neu5Ac have been suggested to be involved in the P. aeruginosa 
binding process as well (25,26).  Therefore, as the first report of profiling 
monosaccharide-binding of clinical P. aeruginosa isolates, results observed in this study 
regarding these three monosaccharides were consistent with the previous findings.  
However, β-Gal, which was considered to be involved in the binding of P. aeruginosa 
(13,38), didn’t show any noticeable binding in our tests.  This suggests that β-Gal might 
not be involved in the lectin binding, even though it’s at the non-reducing end of the 
oligosaccharides that were implicated in the binding of P. aeruginosa.  But it’s still 
possible that β-Gal can be recognized by LecA when it’s conjugated to other structures, 
especially these with high hydrophobicity (39).   
As the binding target of LecB of P. aeruginosa, α-L-fucose didn’t show strong 
binding with the bacteria in various binding solutions.  To confirm this finding, we 
synthesized fluorescent polyacrylamide-based glycopolymers containing α-L-fucoside, 
109 
 
which showed stronger binding with Aleuria aurantia lectin than the commercial PAA-α-
Fuc-Fluor (data not shown).  When the synthesized glycopolymers were used in the P. 
aeruginosa’s binding tests, no strong binding was detected either.  This surprising 
negative binding results can be explained by the observation reported by Jaeger et al. that 
LecB was actually released from the outer membrane of the bacteria by the treatment 
with L-fucose or 4-nitrophenyl α-L-fucose (37,40).  It’s currently under investigation in 
our laboratory whether LecB was released from the outer membrane in the binding tests 
with PAA-α-Fuc-Fluor. 
Also of particular importance is the fact that the sulfation of the monosaccharides 
dramatically changed their binding affinities with the bacteria.  Compared to β-Gal, β-D-
galactose-3-sulfate exhibited much stronger binding with P. aeruginosa; while β-D-
GalNAc-3-sulfate could not be bound by the bacteria, β-GalNAc was one of the three 
strongest binding-monosaccharides.  Taking into consideration that the sulfation level of 
mucin glycans is changed in CF patients (41),  the alteration of the bacterial binding with 
sulfated carbohydrates may have implications in the pathogenesis of P. aeruginosa 
infection in CF patients.   
There’s no obvious difference when the monosaccharide-binding results between 
mucoid P. aeruginosa with non-mucoid, and motile with nonmotile were compared.  
Some isolates cultured in tryptic soy broth (TSB), or cultured in M9 media but harvested 
at the exponential phase (16 h) were also tested with the glycopolymers using the same 
protocol, and a similar binding pattern was observed (Figure IV-6).  When the bacteria 
were subject to a doubled amount of polymers, both α-Gal and SO4-β-Gal showed 
stronger binding results, but not β-GalNAc, the bacterial binding sites of which might be 
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saturated with the routine amount of PAA-β-GalNAc-Fluor (18 µg) used already.  As an 
illustration, the binding results from a clinical isolate CF 3435 was shown here in Figure 
IV-6.   
Besides the observation and analysis by fluorescence microscopy, the 
fluorescence intensities of the bacterial suspensions were also measured on a microplate 
reader and the results were consistent with the microscopy data (Figure IV-7).  Similar to 
the results shown in Figure IV-2, the fluorescence intensities of the different strains and 
isolates also varied noticeably.  This could be partially caused by different sizes and 
shapes of the bacteria (colony-forming unit for each strain and isolates varies from 1.9–
5.7 x 109/mL, as shown in Table II), and also possibly the varied levels of lectin-
expression. 
 
Visualization of monosaccharide-binding of P. aeruginosa 
The binding of glycopolymers by P. aeruginosa ATCC BAA-47 and CF 8314-1 
were visualized by transmission electron microscopy.  The bacteria binding fluorescent 
glycopolymers were incubated with gold-labeled anti-fluorescein isothiocyanate (FITC) 
antibodies.  Heavily gold-labeled bacteria were detected from the binding tests with α-
Gal, β-GalNAc and β-SO4-Gal, where dramatic uneven distributions of labeling were 
observed.  For instance, in the ATCC BAA-47 binding test with PAA-α-Gal-Fluor, only 
~1% of the bacteria were heavily labeled with gold granules (Figure IV-8a), the 
distribution of which was very scarce on the rest of the bacterial population.  In the 
negative-binding tests, the labeling was almost negligible (Figure IV-9).  For CF 8314-1, 
a nonmotile non-mucoid CF isolate, a similar labeling pattern was observed (Figure IV-
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8b).  The high heterogeneity of gold-labeling within the bacterial population agreed with 
the observation that only a very small portion of the bacteria showed observable binding 
with fluorescence microscopy (Figure IV-4).   
 
Flow cytometry results 
Following the glycopolymer-binding tests, some of the resultant bacterial 
suspensions were analyzed on a Beckman Coulter MoFlo XDP cell sorter.  As an 
example, the results from a clinical isolate CF 3435 were presented in Figure IV-10.  The 
three binding monosaccharides, α-Gal, β-GalNAc, and β-SO4-Gal, were well-
differentiated from the other sugars by a small subpopulation of the bacteria (<1.5%) 
showing strong fluorescence, which was consistent with the observations from 
microscopy and transmission electron microscopy.  During the analysis, some of the 
bacteria that were binding PAA-α-Gal-Fluor were isolated by the cell sorter, subcultured 
and retested with PAA-α-Gal-Fluor using the same protocol.  Very similar binding results 
were obtained (data not shown), suggesting the sugar-binding heterogeneity observed in 
the bacterial population was not inheritable.   
In a study published by Scharfman et al.(26), flow cytometry was employed to 
investigate the P. aeruginosa’s binding with PAA glycopolymers.  Instead of two peaks 
in the histograms as presented in Figure IV-10, a shift along the abscissa (fluorescence 
intensity) was reported, suggesting that a majority of the bacteria bound the 
glycopolymers to some extent.  This may be because, after incubation with the polymers, 
the bacteria were analyzed directly by flow cytometry therein without washing, and the 
fluorescence intensity shift can be in part due to non-specific binding.  In contrast, in our 
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study the bacteria were washed stringently to eliminate the non-specific binding, and thus 
presented the two heterogeneous subgroups in the positive-binding tests.   
Growing in the CF lungs, P. aeruginosa developed diverse phenotypes to adapt 
the local microenvironment (2,7).  Even within an isogenic population, remarkable 
phenotypic variations can be observed (6).  The heterogeneity in their carbohydrate-
binding behaviors observed in this study, which reflects varied expression levels of 
lectins, is another phenotypic diversity of the bacteria.  
As a regular procedure performed in many binding tests to further prove their 
specificities, competitive binding experiment was carried out in our study as well.  Since 
there is no appropriate non-fluorescent glycopolymers available to be used as the 
competitor, monovalent glycosides, such as methyl α-D-galactoside (45 mg, 2,500-folder 
excess of the glycopolymers used), were tested as the competitive inhibitor.  But no 
apparent inhibition effects were observed (data not shown).  This can be explained by the 
much higher binding affinities possessed by the multivalent glycopolymers than that of 
any monovalent glycosides (42).  And it’s another target of our ongoing research to 
synthesize glycopolymers with similar structures as the polymers employed herein but 
without fluorophores, to be used as competitive inhibitors in bacterial binding studies.  
Using D-galactose and L-fucose in the sugar inhalation therapy has been effective 
to treat P. aeruginosa infections in CF (12) or other immune compromised patients (20).  
Taking our findings into account, simple α-galactosides, such as methyl α-D-galactose 
and melibiose, would have stronger anti-adhesive effects than D-galactose.  Also, it may 
be beneficial to add GalNAc, β-SO4-Gal and Neu5Ac into the inhalation therapy.  Even 
though binding between lectins and carbohydrates often involves more than one 
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monosaccharide, using simple glycosides in the sugar inhalation treatment is still a 
sensible option, considering the difficulties of acquiring many of the oligosaccharides and 
the potential by-effects of inhaling high-molecular-weight molecules. 
The carbohydrate-binding specificities of P. aeruginosa lectins LecA and LecB 
have been extensively studied (43), but the binding profiles of other adhesins of the 
bacteria, like flagellin, pillin, or LPS are still not very clear.  Using the protocols 
presented here, the monosaccharide-binding profiles of the bacteria were well-established 
on a cellular level.  Our strategy holds promise for applications to other human 
pathogens, like Staphylococcus aureus, Helicobacter pylori, Escherichia coli, to name a 
few, whose carbohydrate-binding behaviors are all of great interest (44,45).   
 
Conclusion 
A protocol using fluorescent glycopolymers together with a panel of analytical 
instruments was established to investigate the P. aeruginosa binding with 
monosaccharides.  Among the eight monosaccharides tested, α-Gal, β-GalNAc, and β-
SO4-Gal showed strong specific binding by all the tested P. aeruginosa laboratory strains 
and clinical isolates, as revealed by fluorescence microscopy, fluorimetry, transmission 
electron microscopy and flow cytometry.  Within an isogenic population, only a small 
percentage (<1.5%) of the bacteria showed strong binding with the glycopolymers, 
revealing an intriguing phenotypic heterogeneity of the bacteria.  Taking these findings 
into consideration, the sugar combinations in anti-adhesion therapy for P. aeruginosa 
infection in CF should be reconsidered.  The treatment might be improved by adding 
GalNAc, β-SO4-Gal and Neu5Ac, and if possible, replacing D-galactose with methyl α-
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D-galactose or melibiose, both containing α-D-galactose residue.  Our results provide new 
perspectives for the pathogenesis of P. aeruginosa infection in CF lungs.  Also, using this 
protocol, the carbohydrate-binding patterns of other bacterial pathogens can be 
determined as well.   
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Table IV-1. Glycopolymers and their pendant monosaccharides used in this study 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations for glycopolymers Pendant monosaccharides 
PAA-α-Gal-Fluor α-D-Galactose 
PAA-β-Gal-Fluor β-D-Galactose 
PAA-α-GalNAc-Fluor α-D-N-Acetylgalactosamine 
PAA-β-GalNAc-Fluor β-D-N-Acetylgalactosamine 
PAA-β-GlcNAc-Fluor β-D-N-Acetylglucosamine 
PAA-β-SO4-Gal-Fluor β-D-Galactose-3-sulfate 
PAA-α-SO4-GalNAc-Fluor β-D-N-Acetylgalactosamine-3-sulfate 
PAA-α-Neu5Ac-Fluor α-D-N-Acetylneuraminic acid 
PAA-α-Fuc-Fluor α-L-Fucose 
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Table VI-2. P. aeruginosa clinical isolates and lab strains tested in this study 
 
Clinical Isolates 
and Lab Strains 
Description  
CF 8314-1  Nonmotile, nonmucoid, CF sputum, green diffusible pigment 
CF 8314-2  Mucoid, CF sputum, from the same patient as the previous isolate  
CF 8981-1  Nonmotile, nonmucoid, CF sputum, restricted growth in M9 media, cultured in TSBa  
CF 8981-2  Mucoid, CF sputum, from the same patient as the previous isolate, brown diffusible pigment 
CF 3318  Motile, CF sputum, restricted growth in M9 media, cultured in TSB 
CF 3247  Motile, CF sputum  
CF 3396  Mucoid, CF sputum  
CF 3443  Small colony variant, CF sputum  
CF 3371  Nonmotile, nonmucoid, dry-looking, CF throat, aggregated in M9 media, cultured in TSB 
CF 3372  Mucoid, CF throat, from the same patient as the previous isolate 
CF 3435  Motile, CF throat  
CF 3437  Motile, CF throat, restricted growth in M9 media, cultured in TSB  
CF 3446  Motile, CF throat  
3380  Motile, non-CF hip infection  
3391  Motile, non-CF sputum  
ATCC BAA-47  PAO1, motile, green diffusible pigment 
ATCC 15442  Motile 
ATCC 33468  Mucoid 
a Tryptic soy broth 
   
  
121 
 
Table VI-3. Lectins used to validate the binding specificities of the glycopolymers 
and their corresponding target carbohydrates 
 
Lectins Target carbohydrates 
Griffonia Simplicifolia lectin I  α-Gal 
Erythrina Cristagalli lectin  β-Gal 
Soybean agglutinin  GalNAc 
Limulus polyphemus lectin α-Neu5Ac 
Wheat germ agglutinin  β-GlcNAc 
Aleuria aurantia lectin  α-Fuc 
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Figure IV-1. The schematic structure of the fluorescent glycopolymers used in this 
study. 
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Figure IV-2. The number of binding bacteria in each test by fluorescence 
microscopy. The resulting bacterial suspensions following binding testes were analyzed 
by fluorescence microscopy. Three photos were taken randomly for each sample, where 
the bacteria binding with the glycoconjugates were enumerated by the software cellSens 
Dimension. α-Gal, β-GalNAc and β-SO4-Gal demonstrated high numbers in all of the P. 
aeruginosa strains and isolates tested, and α-Neu5Ac showed weak binding with some of 
the isolates. The average numbers from triplicate experiments were used here, and error 
bars stand for standard deviations.  
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Figure IV-3. Representative results of bacterial binding test with fluorescent 
glycoconjugates by fluorescence microscopy. A motile P. aeruginosa isolate CF 3435 
was tested with 18 µg of PAA-α-GalNAc-Fluor and PAA-β-GalNAc-Fluor separately. 
Compared with the very weak binding with PAA-α-GalNAc-Fluor (a), strong binding 
was observed with PAA-β-GalNAc-Fluor (b). Scale bar=100 µm. 
  
125 
 
 
 
Figure IV-4. Only a small portion of the P. aeruginosa ATCC BAA-47 population 
showed strong binding with PAA-α-Gal-Fluor. Following the binding tests, the 
bacterial suspension in 1 mL PBS was labeled with 4',6-diamidino-2-phenylindole 
(DAPI, 0.5 nmol) and propidium iodide (20 pmol) for 20 min in the dark, centrifuged, 
resuspended in 1 mL PBS (pH=8), and then analyzed by fluorescence microscopy. Only 
~1% of the bacteria in this view (in green) were binding with the glycoconjugates. Live 
bacteria cells were labeled with DAPI (in blue), and dead with propidium iodide (in red). 
Scale bar=10 µm. 
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Figure IV-5. A higher binding ratio was observed when the bacteria were not 
washed extensively. An aliquot of the bacterial suspensions after the 2 h incubation with 
glycoconjugates was dropped on a glass slide and air-dried.  After the unbound materials 
were rinsed off with PBS, the samples were subject to fluorescence microscopy analysis.  
A higher binding ratio (~2.5%) was observed, but the majority of the bacteria still didn’t 
show any strong binding.  
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Figure IV-6. Monosaccharide-binding pattern of P. aeruginosa CF 3435 cultured in 
different media harvested at different time or tested with double amount of 
glycoconjugates. The culture of CF 3435 in M9 minimum media or TSB were harvested 
at 16 h and tested with fluorescent glycoconjugates using the standard procedure. A 
similar sugar-binding pattern was observed with the culture in M9 media harvested at 35 
h. When tested with double amount of glycoconjugates, α-Gal and SO4-β-Gal showed 
higher binding signals, but not β-GalNAc. 
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Figure IV-7. Normalized fluorescence intensities of the bacterial suspensions from 
the binding tests. In all the strains and isolates of P. aeruginosa tested, the fluorescence 
intensities of the three sugars: α-Gal, β-GalNAc, and β-SO4-Gal, were dramatically 
higher than those from the rest sugars, and α-Neu5Ac bound weakly to some of the 
isolates tested. 
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Figure IV-8. Transmission electron micrographs of a P. aeruginosa laboratory 
strain ATCC BAA-47 (a) and a clinical isolate CF 8314-1 (b) binding with PAA-α-
Gal-Fluor. Following binding tests, the bacterial suspensions deposited on Formvar 
carbon-coated nickel grids were incubated with gold-labeled anti-FITC antibody. Heavy 
labeling was observed in both strains’ tests with α-Gal, but only ~1% of the bacteria were 
heavily labeled. Scale bar=0.5 µm. 
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Figure IV-9. Transmission electron micrographs of a P. aeruginosa lab strain ATCC 
BAA47 (a) and a clinical isolate CF 8314-1 (b) binding with PAA-β-Gal-Fluor. 
Following binding tests, the bacterial suspensions deposited on Formvar carbon-coated 
nickel grids were incubated with gold labeled anti-fluorescein isothiocyanate antibody. 
Only scarce labeling was observed in both strains’ tests with β-Gal (arrowhead). 
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Figure IV-10. Flow cytometry data of P. aeruginosa isolate CF 3435 binding with 
different glycoconjugates. A small portion of bacteria with strong fluorescence (~1.5%, 
indicated with arrows) well-differentiate α-Gal, β-GalNAc, and β-SO4-Gal from the other 
sugars.  
 
  
132 
 
    
 
Figure IV-11. 1H- (a) and 13C-NMR (b) spectra (D2O) of 6-O-α-L-fucopyranosyl-D-
gluconamidoethyl methacrylamide. 
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Figure IV-12. Assigned 1H- (a) and 13C-NMR (b) spectra (D2O) of PAA-α-Fuc. 
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Chapter V. Discussions and Future Directions 
 
 
 
 
 
Among different glycoconjugate structures, linear statistical glycopolymers were 
chosen in this work for their structural comparability with mucins and functional 
versatilities in lectin-binding studies.  They are compatible with a variety of labeling tags 
including different fluorophores, heavy metals and biotin (1,2); they can also be 
conjugated with gold nanoparticles or plastic beads for biocapture assays, or onto a chip 
for glyco-microarray (3);  linking with phospholipids makes them suitable to insert into 
liposome as anchored vectors (4), or into cell membrane to generate a pseudo-glycocalyx 
(5).  A few of these versatilities were exhibited in Chapters II-IV.  
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Chapters II and III present our efforts to synthesize and utilize linear 
glycopolymers, where two different synthesis strategies were explored.  Chapter IV 
demonstrate the use of commercial fluorescent glycopolymers in our pursuit to the 
comprehension of the monosaccharide-binding behaviors of morphologically distinct  
P. aeruginosa cystic fibrosis isolates.  The glycopolymers that were synthesized in 
Chapter III were not adopted in Chapter IV for two reasons.  First, the technical 
difficulties of synthesizing some of the glycopolymers, especially these containing 
sulfated sugars would require an inordinate amount of time.  Second, the synthesized 
glycopolymers still possess lower bacterial-binding avidities than the commercial 
polymers, which give us a target for future research. 
To optimize the performance of the synthesized glycopolymers in lectin-binding 
tests, a number of structural factors need to be considered.  The distribution of different 
monomers in the heterogeneous glycopolymers might affect their binding capacities.  In 
the syntheses described in Chapter III, N-(2-hydroxyethyl) acrylamide (HEAA) was used 
as the spacer to interspace glycomonomers in the copolymer.  Due to the inherent 
structural difference between this spacer monomer and the glycomonomer, their 
polymerization rates are different, causing uneven distributions of the two monomers.  
Taking that into account, 2-gluconamidoethyl methacrylamide (GAEMA), which is 
structurally more comparable with the glycopolymers than N-(2-hydroxyethyl) 
acrylamide, might be a better option as the spacer monomer.  Theoretically, this will lead 
to a more uniform distribution of different monomers.  The structures of HEAA, 
GAEMA and a representative glycomonomer ALAEMA are shown in Figure V-1. 
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Other structural factors of the glycopolymers influencing their lectin-binding 
avidities include the length of the polymers, the linker molecule between the polymer 
backbone and the pendant sugar, and the density of pendant sugars on the polymer.  
Generally, increasing the glycopolymer length improves binding avidity (1), however, a 
longer polymer also causes more cross-linking of the binding targets, which is 
unfavorable in some cases.  Therefore, an optimized range of polymer length needs to be 
determined for bacterial lectin-binding studies.  Also, a longer linker between the pendant 
sugar and polymer backbone normally enhance their binding (6,7).  As discussed in 
Chapter III, by using a larger acceptor sugars (maltose, for example) during the 
glycosylation step in the preparation of the glycopolymers, a longer linker molecule will 
be formed.  Furthermore, instead of using N-(2-aminoethyl) methacrylamide (AEMA) in 
the syntheses of glycomonomers, other acrylamide derivatives with a longer chain can be 
tested as well.  The preparation of one of these possible alternatives is proposed in 
Scheme V-1 as an illustration, which is inspired by syntheses procedures from two 
literatures (8,9).  
To date, the carbohydrate-binding specificities of the two important adhesins of P. 
aeruginosa―pili and flagella are still not fully characterized.  One interesting finding in 
our research is that the mucoid P. aeruginosa isolates, which don’t possess flagella, 
showed similar binding pattern with the bacteria having flagella.  This suggests that the 
binding profile of the flagellar components was probably not depicted in this work, 
possibly because the vigorous processing during the binding tests disengaged some of the 
flagella from the bacteria.  To investigate the sugar-binding of these adhesins, examining 
glycopolymer-binding bacteria that are gently processed and specifically stained for pili 
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and flagella (phosphotungstic acid, for example) by transmission electron microscopy is a 
possible method.  Additionally, a protocol using latex beads coated with isolated P. 
aeruginosa pili or flagella to inspect their binding was reported recently (10).  Combining 
the use of fluorescent glycopolymers with this method offers another possibility to 
investigate the binding specificities of these adhesins.  
One of our discoveries in the P. aeruginosa binding tests is the heterogeneity of 
carbohydrate-binding phenotypes within an isogenic bacterial population.  This might be 
a bet-hedging strategy taken by the bacteria to maximize their survival.  In evolutionary 
biology, bet hedging is defined as a risk-spreading strategy displayed by isogenic 
populations that evolved in unpredictably changing environments favoring different 
phenotypes at different times (11).  In the case of CF lung P. aeruginosa infection, lectin-
mediated adhesion to the airway tract is a key step for the pathogen, however, the 
expression of lectins and some other virulence factors are down-regulated in the 
subsequent biofilms (12-14).  This suggests that different lectin expression levels are 
favored by the bacteria at different infection stages.  Considering the constantly changing 
microenvironment for the bacteria in CF lungs, it’s safe to state that the phenotypic 
heterogeneity of the bacterial sugar-binding observed in this work is a bet-hedging 
strategy. 
As noted in Chapter IV, a great number of bacterial pathogens have been studied 
of their carbohydrate-binding behaviors.  The methodology developed in this work can be 
applied to many other bacteria species, among which S. aureus is the next target of our 
research, because of their prevalence and significance in CF lung infections (15), and the 
presence of adhesins on their surface (16).  
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One of the reasons to study the bacterial carbohydrate-binding is to provide 
references for the anti-adhesion therapy.  As discussed in Chapter IV, based on the 
findings in this work, the formula of the anti-adhesion therapy for CF patients with P. 
aeruginosa infection should be reconsidered.  Improved treatment might be achieved by 
adding GalNAc and replacing D-galactose with melibiose.  L-Fucose has been shown in 
vitro to restore the compromised ciliary movement caused by LecB (17).  Therefore, even 
though α-L-Fuc didn’t show observable binding with P. aeruginosa in our tests, it should 
be still beneficial to include it in the nebulizer when treating the infection. 
Several reported unsuccessful clinical trials using inhibitor for one particular 
lectin to prevent or treat bacterial infections (18,19) imply the importance of a thorough 
characterization of the carbohydrate-binding profile of the pathogen, where a cocktail of 
competitive carbohydrates might be more effective.  Employing the protocol presented 
herein, it’s possible to fully characterize the monosaccharide-binding profiles of various 
pathogens, which may promote the efficacies of anti-adhesion therapies. 
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Figure V-1. Chemical structure of HEAA, GAEMA and ALAEMA  
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Schemes V-1. Synthesis of N-(5-aminoxylitolyl) methacrylamide hydrochloride―a 
possible alternative for AEMA in the preparation of glycomonomers 
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